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Abstract 
Anni Vainio. Molecular Methods for the Epidemiological Analysis of Methicillin-
Resistant Staphylococcus aureus (MRSA)  and Streptococcus pneumoniae. National 
Institute for Health and Welfare (THL), Research 71, 164 pages. Tampere, Finland 
2012. ISBN 978-952-245-554-3 (printed); ISBN 978-952-245-555-0 (pdf). 
 
Methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae 
are major health problems worldwide, both found in symptomless carriage but also 
causing even life-threatening infections. The aim of this thesis was to characterise 
MRSA and S. pneumoniae in detail by using several molecular typing methods for 
various epidemiological purposes: clonality analysis, epidemiological surveillance, 
outbreak investigation, and virulence factor analysis.  
 
The characteristics of MRSA isolates from the strain collection of the Finnish 
National Infectious Disease Register (NIDR) and pneumococcal isolates collected 
from military recruits and children with acute otitis media (AOM) were analysed 
using various typing techniques. Antimicrobial susceptibility testing, pulsed-field 
gel electrophoresis (PFGE), multilocus sequence typing (MLST), spa typing, 
staphylococcal cassette chromosome mec (SCCmec) typing, and the detection of 
Panton-Valentine leukocidin (PVL) genes were performed for MRSA isolates. 
Pneumococcal isolates were analysed using antimicrobial susceptibility testing, 
serotyping, MLST, and by detecting pilus islet 1 (PI-1) and 2 (PI-2) genes. The 
epidemiological background data for the pneumococcal pneumonia outbreak 
investigation were retrieved by interviewing all the military recruits involved in the 
outbreak. In addition, the medical records of five hospitalised recruits were reviewed. 
Forty-four previously recognised epidemic MRSA strains (EMRSA) in Finland were 
grouped into 26 PFGE clusters, 20 MLST sequence types (ST) belonging to 12 
clonal complexes (CC), and 27 spa types divided into four spa clonal complexes 
(spa CC). The CC8, spa CC 051/008, and SCCmec type IV were the most prevalent 
among these strains. In addition, 52% of the strains were multiresistant to 
antimicrobials. FIN-4 and FIN-16 isolates mainly associated with spa type t172 
(2006: 81% and 1997–2006: 92%) and t067 (2006: 93% and 1997–2006: 80%), 
respectively. The 124 MRSA blood isolates from 1997–2006 were divided into 19 
PFGE types and 38 spa types. The most prevalent spa types were t067 (32%), t041 
(13%) and t172 (10%).  
Typeability, discriminatory power, concordance, Wallace coefficient, and the 
consumption of time and money was compared between MRSA typing methods. 
The overall typeability of the methods was high, above 89%. PFGE clusters, MLST 
and spa typing showed a high discriminatory power. The concordance was highest 
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between MLST and PFGE clusters. spa typing demonstrated a high probability to 
predict PFGE, MLST ST and MLST CC, as well as SCCmec types, depending on 
the study material. Compared to PFGE, spa typing was found to be more expensive 
but approximately four times faster to perform.  
S. pneumoniae serotype 7F and genotype ST2331 associated with an outbreak of 
pneumonia and nasopharyngeal carriage among 43 military recruits in Finland in 
2006. Of these recruits, five (12%) were hospitalised due to pneumonia and two of 
them were found to have positive blood cultures for S. pneumoniae. Forty-two per 
cent of the military recruits carried S. pneumoniae in their nasopharynx. Half of 
these isolates had the same serotype 7F, ST2331. 
Among the 75 pneumococcal isolates from middle ear fluid (MEF) and/or 
nasopharyngeal aspirate (NPA) samples of children with acute otitis media (AOM), 
14 different serotypes were detected. PI-1 genes were present among 20% of the 
isolates. PI-2 genes were not found. The 52 isolates from 33 children genotyped by 
MLST belonged to 30 different STs and 18 known CCs. PI-1 was associated with 
genotype CC490 and serotypes 6A, 6B and 9V.  
Several international community- and hospital-associated MRSA clones were 
recognised in Finland. The genetic diversity among MRSA FIN-4 isolates and 
among FIN-16 isolates was low. Overall, MRSA blood isolates from 1997 to 2006 
were genetically diverse. spa typing was found to be a highly discriminatory, rapid 
and accurate typing method and it also qualifies as the primary typing method in 
countries with a long history of PFGE-based MRSA strain nomenclature. However, 
additional typing by another method, e.g. PFGE, is needed in certain situations to be 
able to provide adequate discrimination for epidemiological surveillance and 
outbreak investigation.  
An outbreak of pneumonia was associated with one pneumococcal strain among 
military recruits, previously healthy young men living in a crowded setting. The 
pneumococcal carriage rate after the outbreak was found to be exceptionally high. 
PI-1 genes were detected at a rather low prevalence among pneumococcal isolates 
from children with AOM. However, the study demonstrated that PI-1 has existed 
among pneumococcal isolates prior to pneumococcal conjugate vaccine and the 
increased antimicrobial resistance era. Moreover, PI-1 was found to associate with 
the serotype rather than the genotype.  
Keywords: clonality; methicillin-resistant Staphylococcus aureus; molecular typing;  
outbreak; pilus; Streptococcus pneumoniae; surveillance 
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Metisilliini-resistentti Staphylococcus aureus (MRSA) ja Streptococcus pneumoniae 
aiheuttavat merkittäviä terveysongelmia maailmanlaajuisesti. Molemmat voivat löytyä 
oireettomilta kantajilta, mutta ne voivat aiheuttaa myös hengenvaarallisia infektioita. 
Väitöskirjan tavoitteena oli karakterisoida MRSA- ja S. pneumoniae-bakteereita 
tarkemmin käyttämällä useita tyypitysmenetelmiä erilaisiin epidemiologisiin 
tutkimuksiin: klonaalisiin analyyseihin, epidemiologiseen seurantaan, epidemia-
selvityksiin ja virulenssitekijöiden analysointiin. 
Tartuntatautirekisterin kantakokoelman MRSA-kantojen ja varusmiehiltä sekä akuuttia 
välikorvantulehdusta sairastavilta lapsilta kerättyjen pneumokokkikantojen 
ominaisuuksia analysoitiin käyttämällä erilaisia tyypitysmenetelmiä. MRSA-kannoille 
käytettiin antibioottiherkkyystestausta, pulssikenttägeelielektroforeesia (PFGE), MLST-
menetelmää, spa- ja SCCmec-tyypitystä sekä Panton-Valentin-leukosidiini- (PVL) 
geenien havaitsemista. Pneumokokkikantoja analysoitiin antibioottiherkkyystestauksella, 
serotyypityksellä, MLST-menetelmällä ja määrittämällä pilus-1 (PI-1) ja -2 (PI-2) 
geenien läsnäoloa. Pneumokokin aiheuttamassa keuhkokuume-epidemiassa taustatieto 
hankittiin haastattelemalla kaikki epidemiaan liittyvät varusmiehet. Lisäksi tarkasteltiin 
viiden sairaalahoitoon joutuneen varusmiehen sairaskertomuksia.  
Neljäkymmentäneljä jo aikaisemmin tunnistettua suomalaista epideemistä MRSA-kantaa 
(EMRSA) jakaantui 26 PFGE ryhmäksi ja 20 MLST sekvenssityypiksi (ST), jotka 
kuuluivat 12 klonaaliseen kompleksiin (CC). Lisäksi näiden kantojen joukosta löydettiin 
27 spa-tyyppiä, jotka jakaantuivat neljään spa-klonaaliseen kompleksiin (spa CC). 
EMRSA-kantojen joukossa yleisimpiä olivat CC8, spa CC 051/008 ja SCCmec-tyyppi 
IV. Lisäksi 52 % kannoista oli resistenttejä useille antibiooteille. FIN-4-kannat 
yhdistettiin pääasiassa spa-tyyppiin t172 (2006: 81 % ja 1997-2006: 92 %) ja FIN-16-
kannat spa-tyyppiin t067 (2006: 93 % ja 1997-2006: 80 %). Vuosilta 1997-2006 verestä 
eristetyistä MRSA-kannoista 124 jakaantui 19 PFGE-tyypiksi ja 38 spa-tyypiksi. 
Yleisimmät spa-tyypit olivat t067 (32 %), t041 (13 %) ja t172 (10 %). 
Tyypityksen onnistumista, vastaavuutta, Wallace-kerrointa, sekä tyypityksiin kuluvaan 
aikaa ja kustannuksia vertailtiin eri MRSA-tyypitysmenetelmien kesken. Kaiken 
kaikkiaan yli 89 % kannoista saatiin tyypitettyä. Kaikkein erottelevimpia menetelmiä 
olivat PFGE-menetelmä (ryhmätasolla), MLST ja spa-tyypitys. Vastaavuus oli korkeinta 
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MLST- ja PFGE-menetelmien (ryhmätasolla) välillä. spa-tyypitys ennusti PFGE-, MLST 
ST-, MLST CC- ja SCCmec-menetelmien tyypitystulosta suurella todennäköisyydellä, 
mutta tutkimusmateriaalista riippuen. spa-tyypitys oli kalliimpaa mutta nopeampi 
suorittaa kuin PFGE.  
Pneumokokin serotyppi 7F ja genotyyppi ST2331 yhdistettiin keuhkokuume-epidemiaan 
ja nenänielun kantajuuteen 43 varusmiehellä Suomessa vuonna 2006. Viisi (12 %) 
varusmiehistä joutui sairaalahoitoon keuhkokuumeen vuoksi ja kahdella heistä kasvoi 
pneumokokki veriviljelynäytteestä. Varusmiehistä 42 % kantoi pneumokokkia 
nenänielussaan. Puolet varusmiesten nenänieluista löydetyistä pneumokokeista olivat 
samaa serotyppiä 7F, ST2331.  
Akuuttia välikorvantulehdusta sairastavien lasten välikorvan eritteestä ja/tai nenä-nielun 
aspiraatiosta eristetyistä 75 pneumokokkikannasta löytyi 14 erilaista sero-tyyppiä. 
Kannoista 20 % kantoi PI-1-geenejä. PI-2-geenejä ei löydetty ollenkaan. 
Viisikymmentäkaksi kantaa, jotka eristettiin 33 lapselta ja genotyypitettiin MLST-
menetelmällä, kuuluivat 30 eri sekvenssityyppiin ja 18 tunnettuun klonaaliseen 
kompleksiin. PI-1 yhdistettiin genotyyppiin CC490 ja serotyyppeihin 6A, 6B ja 9V.  
Useita kansainvälisiä sairaalaperäisiä ja avohoitoon liittyviä MRSA-klooneja on 
tunnistettu Suomessa. Geneettinen monimuotoisuus oli FIN-4 ja FIN-16 MRSA-kantojen 
joukossa alhainen. Yleisesti ottaen verestä eristetyt MRSA-kannat vuosilta 1997-2006 
olivat geneettisesti erilaisia. spa-tyypitys oli hyvin erottelukykyinen, nopea ja tarkka 
tyypitysmenetelmä ja se täyttää vaatimukset ensisijaisena tyypitysmenetelmänä myös 
maissa joilla on pitkä historia MRSA-kantojen nimeämisestä PFGE-tyypityksellä. 
Lisätyypitysmenetelmiä, esimerkiksi PFGE-menetelmää, kuitenkin tarvitaan tietyissä 
tilanteissa, jotta saavutetaan riittävä erottelukyky epidemiologista seurantaa ja 
epidemiaselvitystä varten.  
Ahtaissa oloissa elävien, aiemmin terveiden varusmiesten keuhkokuume-epidemiaan 
liittyi yksi pneumokokkikanta. Epidemian jälkeen varusmiesten pneumokokki-
kantajuuden taso oli poikkeuksellisen korkea.  
Melko pieneltä osalta pneumokokkikannoista, jotka oli eristetty akuuttia 
välikorvantulehdusta sairastavilta lapsilta, löydettiin PI-1-geenejä. Tutkimus kuitenkin 
osoitti, että PI-1 on ollut olemassa jo ennen pneumokokin konjugaattirokotteen käyttöä ja 
lisääntynyttä antibioottiresistenttiyttä. Lisäksi PI-1 liittyi ennemmin serotyyppiin kuin 
genotyyppiin. 
Avainsanat: epidemia; klonaalisuus; metisilliini-resistentti Staphylococcus aureus; 
molekyylityypitys; pilus; seuranta; Streptococcus pneumoniae. 
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1 INTRODUCTION 
Staphylococcus aureus is able to cause a wide variety of different diseases, ranging 
from superficial skin inflammation to severe invasive infections such as bacteraemia 
(355). Methicillin-resistant Staphylococcus aureus (MRSA) has become a major 
problem worldwide. MRSA can cause both community-acquired and nosocomial 
infections. In Finland, an increase in the annual numbers of MRSA cases was 
observed from 121 in 1997 to 1772 in 2008. However, the MRSA situation 
improved in 2009, when 1267 cases were registered in the National Infectious 
Diseases Register (358). Accurate genotyping methods are required for national 
MRSA surveillance, outbreak investigations and international comparisons. Several 
different genotyping techniques for MRSA have been used in Finland. 
Macrodigestion of the whole bacterial chromosome, pulsed-field gel electrophoresis 
(PFGE), served as a primary typing method to distinguish different MRSA strains 
for several years (353). However, spa typing, which analyses the polymorphic X-
region of protein A of S. aureus, replaced PFGE, and is now used as the first-line 
typing tool in Finland (329, 351). Multilocus sequence typing (MLST) of seven 
housekeeping genes and analysis of a methicillin resistance genetic element, 
staphylococcal cassette chromosome mec (SCCmec), are used as additional typing 
methods. In addition, MLST and SCCmec typing are valuable for understanding the 
evolutionary relationship between MRSA clones (96, 98, 267, 269). 
 
Streptococcus pneumoniae causes severe invasive infections such as meningitis, 
bacteraemia and pneumonia, and non-invasive infections such as sinusitis and acute 
otitis media worldwide (304). Pneumococci are also normal inhabitants of 
nasopharyngeal mucous membranes in healthy children and adults (263). Although 
pneumococcal conjugate vaccine (PCV) is increasingly being used, pneumococcal 
infections caused by non-vaccine serotypes and the antimicrobial resistance of S. 
pneumoniae strains have become a major public health issue (45, 89, 150). In 
Finland, over 800 new bacteraemic S. pneumoniae infections are registered annually 
(358). Careful monitoring of the serotype distribution, antimicrobial susceptibility 
pattern and clonality of the strains is needed for active national surveillance of the 
disease burden and the efficacy of the recently launched national immunisation of all 
children with PCV. Molecular typing methods, such as MLST, provide excellent 
tools for genotyping of the strains and for better understanding of pneumococcal 
transmission in outbreaks (99). In addition, analysis of pneumococcal virulence 
protein genes is of interest for understanding the pathogenesis of pneumococcal 
diseases.   
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The purpose of this thesis was to characterise Streptococcus pneumoniae and 
methicillin-resistant Staphylococcus aureus in detail by using several molecular 
typing methods for various epidemiological purposes. Firstly, the aim was to 
examine the characteristics and clonality of EMRSA, to evaluate and compare 
typing methods for national laboratory-based surveillance of MRSA. Secondly, the 
purpose was to study the outbreak and carriage of S. pneumoniae in a crowded 
community setting, and to study virulence factors of S. pneumoniae isolated from 
children with AOM infection. 
Introduction
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2 REVIEW OF THE LITERATURE  
2.1 Staphylococcus aureus 
2.1.1 Characteristics of S. aureus 
Staphylococcus aureus is a Gram-positive, facultative anaerobic, catalase- and 
coagulase-positive, coccus-shaped bacterium. S. aureus is a human pathogen and 
can also be found among domestic animals such as pigs, dogs and horses. The 
typical 24-h S. aureus colonies are large, cream-yellow to orange pigmented, and !-
haemolytic on blood agar (16). The outermost layers of S. aureus are important for 
protection against many different harmful molecules in their environment. The cell 
wall of S. aureus consists of peptidoglycan and teichoic acids, which are connected 
to either pepticoglycan or cytoplasmic membrane (396). In addition, many 
staphylococcal surface proteins are anchored to the cell wall. More than 90% of all 
clinical isolates of S. aureus strains are covered by a polysaccharide capsule, and a 
total of 11 putative capsule serotypes have been described so far, of which the most 
prevalent serotypes are 5 and 8. Both of these serotypes are prevalent among isolates 
from clinical infections as well as from commensal sources (262). The S. aureus 
genome roughly consists of a single circular chromosome with insertion sequences, 
transposons and genomic islands (12). Prophages and pathogenicity islands, in 
particular, are considered to play important roles in the evolution and virulence of S. 
aureus (12). To date, several complete S. aureus genomes have been sequenced by 
various genome sequencing projects (170, 250). Genomes of S. aureus are 
approximately 2.9 megabase pairs (Mbp) in size with a relatively low G+C content  
(12).  
2.1.2 Diseases and carriage 
Staphylococcus aureus can cause a wide variety of diseases, ranging from mild skin 
infections to fatal forms of bacteraemia.  The most common infection by S. aureus is 
superficial skin inflammation with a furuncle or boil. Other skin and subcutaneous 
infections caused by S. aureus include folliculitis, carbuncles, cellulitis, mastitis and 
impetigo. S. aureus can also cause chronic skin and soft tissue infections within 
human populations with some underlying disorders. More severe S. aureus 
infections include osteomyelitis, pneumonia, arthritis, scalded skin syndrome, 
endocarditis, myocarditis, pericarditis, and bacteraemia (64, 354). Community-
acquired pneumonia caused by S .aureus is not common, but does occur. In hospital 
settings, S. aureus can cause pneumonia, with 15–20% mortality. S. aureus is 
reported to be the most common cause of nosocomial pneumonia and surgical site 
infections, and was the third most common cause of nosocomial blood stream 
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infections in intensive care units (ICUs) in the US from 2000 to 2004 (354). In 
addition, in 2005, there were an estimated 478 000 hospitalisations with a diagnosis 
of S. aureus infection and 14 million outpatient healthcare visits for suspected S. 
aureus skin and soft tissue infections in the US (50). 
 
S. aureus is a leading cause of bacteraemia and is associated with high morbidity 
and mortality (65). Bacteraemia often originates from different infection sources 
such as pneumonia, osteomyelitis, deep tissue abscesses and septic pulmonary 
emboli (302). Bacteraemia can also originate from foreign bodies such as 
intravenous catheters and endoprostheses (354). In the Calgary Health Region in 
Canada, the annual incidence of S. aureus bacteraemia was 19.7 cases/100 000 
population during 2000–2006, and in Olmsted County, Minnesota, 33.4 
cases/100 000 population during 1998–2005 (92, 209). According to the European 
Antimicrobial Resistance Surveillance Network (EARS-Net) (former European 
Antimicrobial Resistance Surveillance System, EARSS), rates of Staphylococcus 
aureus bacteraemia in Europe in 2003 ranged from 14 cases/100 000 inhabitants in 
Spain to 32 cases/100 000 inhabitants in Ireland (361). 
 
In Finland, the annual incidence of bloodstream infection caused by S. aureus rose 
by 55% during 1995–2001 (from 11 cases/100 000 population in 1995 to 17 in 2001) 
(220). According to the National Infectious Disease Register (NIDR), S. aureus has 
annually caused approximately 1200 bacteraemic infections in the past five years 
(Figure 1) (359). In addition, S. aureus was reported to be the second most common 
pathogen to cause bloodstream infection among the working-age population (from 
15 to 64 years old) and the elderly (65 years old and older) during 1995–2009 (358).  
 
 
Figure 1. S. aureus blood culture findings in Finland during 1997–2009 (358).  
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Several diseases caused by S. aureus are toxin-mediated, including food poisoning, 
impetigo, toxic shock syndrome (TSS) and necrotising pneumonia. Staphylococcal 
enterotoxins ingested via contaminated food cause self-limiting staphylococcal food 
poisoning. The symptoms of staphylococcal food poisoning include nausea, 
vomiting, headache, and less commonly diarrhoea (354). TSS is caused by toxic  
shock syndrome toxin 1, which is a potent superantigen (321, 368). Menstrual TSS 
is typically associated with use of highly absorbent tampons among previously 
healthy women (327). Non-menstrual TSS may result from any primary 
staphylococcal infection, or from colonisation with a toxin-producing strain of S. 
aureus (207). The symptoms of TSS include high fever, hypotension, rash and the 
involvement of multiple organ systems (77, 207). 
  
S. aureus colonises the skin and mucosal surfaces of humans. Although multiple 
sites in the body can be colonised by S. aureus, the anterior nares of the nose are the 
most consistent carriage site in humans (385). Other typical sites for S. aureus 
colonisation include the skin, perineum, pharynx, and less frequently the 
gastrointestinal tract, vagina and axillae (385). In longitudinal S. aureus carrier 
studies, three different carrier patterns have been historically assigned: persistent 
carriers, intermittent carriers and noncarriers (192). However, the criteria used to 
assign an individual to these carriage patterns vary and most of the studies have used 
a cross-sectional study design with a single nasal culture. In 2009, van Belkum and 
co-workers suggested that there are only two types of nasal S. aureus carriers: 
persistent and other (376). In studies performed in the United States, the prevalence 
of nasal colonisation with S. aureus has been estimated to be around 30%, and it was 
found to be highest among 6- to 7-year-old children (50, 202). In a recent study in 
Lebanon, the overall S. aureus nasal carriage rate between 2006 and 2007 was 
38.4% (134). Nasal carriage of S. aureus, especially persistent nasal carriage, has 
been identified as a risk factor for the development of infections in various settings. 
It is especially a major risk factor in certain groups of patients, such as patients 
undergoing surgery and haemodialysis, and patients with intravascular devices and 
HIV infection (192). 
2.1.3 Virulence factors and pathogenesis 
In general, the ability of bacteria to cause disease in humans is mainly due to 
evasion of the host immune system. S. aureus can express an extensive number of 
different virulence factors, playing a role in the pathogenesis of infection. The form 
and severity of the disease are a result of the complicated interplay between the 
activities of S. aureus virulence factors of the infecting strain and host defence. A 
virulence factor may have several functions in pathogenesis, and multiple virulence 
factors may perform the same function. Staphylococcal pathogenesis is 
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multifactorial, involving three classes of factors that are directly or indirectly 
injurious: secreted proteins, cell-surface-bound proteins, and cell surface 
components. Secreted proteins, including superantigens (e.g. toxic shock syndrome 
toxin-1, enterotoxins A-D), cytotoxins [e.g. Panton-Valentine leukocidin (PVL), 
"-,!-,#-,$-haemolysin], and tissue-degrading enzymes (e.g. lipases, proteases), 
enable bacteria to invade and destroy the local cellular and structural elements of 
host tissue and organs (123, 257).  
 
PVL toxin is encoded by two genes located on the prophage (81). It is lethal to 
neutrophils and causes tissue necrosis by forming pores in cell membranes, and it is 
associated with skin and soft tissue infections and severe necrotising pneumonia 
(204, 214). PVL production has also been associated with community-acquired 
methicillin-resistant S. aureus (CA-MRSA) strains (381). S. aureus has numerous 
surface proteins termed microbial surface components recognising adhesive matrix 
molecules (MSCRAMMs), including fibronectin-binding protein, fibrinogen-
binding protein, collagen-binding protein, other adhesins, and antiopsonins (257). 
MSCRAMMs mediate adherence to host tissues, bacterial cells, the extracellular and 
to inert surfaces and appear to play a key role in the initiation of endovascular 
infections, bone and joint infections, and prosthetic-device infections (109, 123).  
 
The best known surface protein of S. aureus is staphylococcal protein A (Spa). Spa 
was isolated first time from S. aureus after lysostaphin digestion in 1972 (335). It 
comprises five nearly identical Ig-binding domains, a polymorphic region X and C-
terminal cell wall attachment sequence (133, 334, 369). The structure of spa gene is 
represented more thoroughly in the section 2.3.8. The X region of the spa gene 
contains a highly polymorphic sequence that is composed of repeats of 24 bp (112). 
Spa binds to the Fc region of IgG and blocks its normal function. This inhibits 
phagocytosis and can disguise the bacterium from the innate immune system by 
preventing opsonisation-dependent activation of the complement cascade (395). 
Protein A has also been reported to be capable of binding to platelets via the 
gC1qR/p33 receptor and the von Willebrand factor (142, 252). In addition, spa 
typing is a widely used genotyping method to compare S. aureus isolates, due to the 
highly variable X-region (111). Cell surface components, including the 
polysaccharide capsule and components of the cell wall peptidoglycan, have 
different activities in the pathogenesis of S. aureus. Mucoid capsules can block 
phagocytosis by masking complement factor C3b bound to the cell wall (72). 
However, the role of the capsules of S. aureus in pathogenesis is controversial.    
 
The genes coding for staphylococcal virulence factors are controlled by a complex 
regulatory network. The surface protein genes are expressed shortly after the 
initiation of the exponential growth phase, when they are needed during the 
establishment of infection to aid in adherence to host tissues and to protect the 
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bacteria from host defences such as opsonisation-phagocytosis and complement-
mediated killing. Many of the genes encoding secreted enzymes and cytotoxins are 
expressed primarily during the postexponential growth phase to aid in spreading, the 
acquisition of nutrients and killing of phagocytes (257). The accessory gene 
regulation (agr) locus is the main global regulatory system of S. aureus (395). In 
addition, three other two-component signalling modules are known to be involved in 
the regulation of staphylococcal virulence genes. Moreover, environmental factors 
such as pH, temperature, O2 and CO2 levels also affect the overall regulatory system 
by helping the bacterium to recognise and respond appropriately to its local 
environments (257, 395). 
 
Although S. aureus has traditionally been regarded as an extracellular pathogen, 
multiple studies have shown that it can survive in a variety of eukaryotic cells, 
including endothelial cells, epithelial cells, fibroblasts, osteoblasts and keratinocytes. 
In addition, bacterial survival within human monocyte-derived macrophages and 
neutrophils has also been demonstrated (115). Intracellular survival of S. aureus can 
contribute to the persistent and /or recurrent nature of certain infections. S. aureus 
mutants known as ‘small colony variants’ (SCVs) are slow-growing colonies that 
are 10-fold smaller than normal and have certain characteristics such as decreased 
pigment formation, low coagulase activity, reduced haemolytic activity, decreased 
toxin production and resistance to aminoglycosides. Small colony variants have the 
ability to persist intracellularly and to cause persistent and recurrent infections (393). 
2.1.4 Methicillin-resistant Staphylococcus aureus (MRSA) 
In 1942, two years after the introduction of penicillin for medical use, the first 
penicillin-resistant S. aureus isolates were observed. Since 1960, approximately 
80% of all S. aureus isolates have been penicillin-resistant. In addition, S. aureus 
developed methicillin resistance in 1961, only two years after its introduction. The 
resistance to methicillin and all other !–lactam antibiotics developed due to the 
acquisition of the mecA gene (81). This gene encodes a 78 kilodalton (kDa) 
additional penicillin-binding protein (PBP) 2a. PBPs are transpeptidases that 
catalyse the formation of cross-bridges in bacterial cell wall peptidoglycan. In 
methicillin-sensitive S. aureus (MSSA), !–lactam antibiotics bind to the native PBPs 
of the cell wall, disrupting the synthesis of the peptidoglycan layer and resulting in 
the death of the bacterium. Since PBP2a has a low affinity for all !–lactam 
antibiotics, synthesis of the peptidoglycan layer is not disrupted and MRSA can 
continue to grow normally (22). The mecA gene is regulated by the repressor MecI 
and the trans-membrane !–lactam-sensing signal-transducer MecR1. In the absence 
of !–lactam antibiotics, MecI represses the transcription of both mecA and mecR1-
mecI. In the presence of the !–lactam antibiotics, MecR1 is autocatalytically cleaved 
and the metalloprotease domain of the MecR1 becomes active. This metalloprotease 
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cleaves MecI, allowing the transcription of mecA and subsequent production of 
PBP2a (22).  
 
The mecA gene is located on a mobile genetic element ranging from 20 kilobase 
pairs (kbp) to more than 100 kbp in size and designated the staphylococcal cassette 
chromosome mec (SCCmec) (166). SCCmec is considered to have originated from 
other bacterial species and integrated into the chromosome of S. aureus. In addition, 
it is hypothesised that SCCmec is distributed through horizontal transmission 
between staphylococcal species (165, 183, 248, 295). SCCmec consists of the mec 
complex, cassette chromosome recombinase (ccr) complex, joining regions (J), and 
directly repeated 15-base-pair (bp) core sequences at the both ends. SCCmec is 
present at a specific site on the chromosome, the SCCmec attachment site (attBscc), 
at the 3’ end of an open reading frame with an unknown function (orfX) (Figure 2) 
(165, 166).  
 
 
 
Figure 2. Simplified diagram of SCCmec. Grey regions indicate chromosome 
regions that are outside the SCCmec elements. J1-J3 indicates joining regions. The 
diagram is based on information from (155, 166). 
 
Currently, ten main types of SCCmec (types I-X) and several variants have been 
designated based on differences in structure and size (24, 81, 151, 166, 167, 193, 
212, 268, 403). SCCmec types I, IV, V, VI, and VII mainly cause !–lactam 
antibiotic resistance, while SCCmec types II and III cause multiresistance due to 
additional drug resistance genes integrated into SCCmec (81). The SCCmec type is 
classified by the mec complex (a region containing mecA, mecR, IS/mecI, IS431) 
and the ccr gene complex (a region containing recombinase genes such as ccrA, 
ccrB or ccrC). SCCmec can be further classified into subtypes based on different J 
regions (JI-J3), which border the mec and ccr complexes (81, 82, 166). S. aureus can 
also harbour additional resistance genes at other sites of the genome, such as 
transposons and plasmids (216). In general, the majority of community-acquired 
MRSA (CA-MRSA) isolates harbour SCCmec type IV, V or VII, while SCCmec 
types I, II and III are considered to mainly occur among hospital-acquired MRSA 
(HA-MRSA) isolates (81, 249).  
 
J1 
ccr gene 
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J3 
mec gene 
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J2 
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Most MRSA strains have heterogeneous expression of methicillin resistance (300). 
The majority of cells are susceptible to low concentrations of methicillin, and a 
small proportion of cells can grow at high methicillin concentrations. Such highly 
resistant subclones may be partly associated with expression of the mecA gene, 
which apparently requires the genetic inactivation of the MecI repressor, and due to 
mutation events in other genes of the staphylococcal genome (22, 254, 305). Many 
of these chromosomal genes affecting methicillin resistance levels, independent of 
SCCmec, have been identified, and many of them are involved in peptidoglycan 
biosynthesis, such as fem (factors essential for methicillin resistance) and aux 
(auxillary) factors (22, 23, 78). Staphylococci are also able to acquire mecA-
independent methicillin resistance, for instance due to overexpression of PBP2 
and/or PBP4, and changes in their penicillin affinity. Low-level methicillin 
resistance of borderline resistant S. aureus (BORSA) strains results from the 
hyperproduction of penicillinase (52, 229). The challenge is to distinguish 
penicillinase hyper-producing strains from mecA-positive MRSA strains, without 
detecting the mecA-gene by PCR.  
 
In 2003–2004, approximately 1.5% (4.1 million persons) of the US population were 
estimated to be colonised in the nose with MRSA, and in 2004, 64% of S. aureus 
infections in intensive-care units were caused by MRSA (50). In 2005, the incidence 
of invasive MRSA disease in 9 US communities was 31.8 cases/100 000 people 
(191). MRSA is also an increasing problem throughout Europe. In 2006, the 
proportion of MRSA isolates among blood and cerebrospinal fluid isolates was 
reported as 25% or higher in 12 out of 28 countries [mainly southern European 
countries, the United Kingdom (UK) and Ireland], while in northern parts of Europe 
the proportion was below 4% (90). In Finland, the annual number of MRSA cases 
has increased from 121 in 1997 to 1772 in 2008 (Figure 3) (359). However, the 
MRSA situation improved in 2009, when 1267 cases were registered in the National 
Infectious Diseases Register (NIDR) and the situation remained unchanged in 2010 
(359, 360). In both years a quarter of these were diagnosed from samples taken from 
the nose or the nostrils (358, 360). The proportion of MRSA strains among S. aureus 
findings from blood rose above 3% in 2004 and has been around 2% in 2009-2010 
(Figure 4) (358, 360). 
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Figure 3. Annual number of MRSA cases and incidence/100 000 inhabitants in 
Finland during 1997–2009 (359). 
MRSA cases: laboratory notifications included both asymptomatic carriers and cases 
with clinical disease. 
 
 
 
Figure 4. Annual number of MRSA blood culture findings and the proportion of 
MRSA among all the S. aureus blood culture findings during 1997–2010 (358, 360).  
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To date, there is no convincing evidence that MRSA is generally more virulent 
than MSSA. SCCmec does not contain any virulence genes, and thus is not 
directly associated with the possibly enhanced virulence of MRSA. However, 
some epidemiological studies, including a meta-analysis, have revealed increased 
morbidity and/or mortality from nosocomial MRSA (67, 233). In contrast, other 
studies have demonstrated no increase in mortality with nosocomial MRSA 
bacteremia or ventilator-associated pneumonia compared with MSSA infections 
(66, 401). However, according to a recent meta-analysis, colonisation by MRSA 
was associated with a 4-fold increase in the risk of infection compared with 
MSSA (306). Other causes than differences in virulence may explain the poorer 
outcomes with MRSA, such as the severity of illness, inadequate or ineffective 
therapy, and prolonged hospital stays (299, 306, 325). Although the question of 
whether MRSA is more virulent than MSSA remains unresolved, it is clear that 
MRSA infections are associated with greater costs and limited treatment options 
(66, 94, 291).   
 
In 1997, a new threat emerged from Japan: vancomycin intermediate-resistant S. 
aureus (VISA)(156). More VISA cases were subsequently reported from other 
countries around the world. The mechanism of resistance in VISA strains is 
mediated by mutations and altered expression of certain genes, resulting in a 
thickened cell wall that prevents vancomycin from properly functioning (71). 
Vancomycin-resistant MRSA (VRSA) was first noticed in 2002, and around ten 
VRSA cases have since been reported in the US. In addition to the mecA gene, 
VRSA strains harbour a plasmid-borne transposon Tn1546 element with a vanA 
gene cluster following conjugation from a glycopeptide-resistant Enterococcus 
strain (275, 330).  Although VISA and VRSA strains seem to be rare and limited, 
the potential for spread of such isolates should not be underestimated.  
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2.2 Streptococcus pneumoniae  
2.2.1 Characteristics of S. pneumoniae 
Streptococcus pneumoniae or pneumococcus is a Gram-positive, facultatively 
anaerobic, catalase-negative diplococcus bacterium that typically produces 
greenish haloes (alpha-haemolysis) on blood agar. Pneumococci may have a 
mucoid colonial appearance due to the production of varying amounts of capsular 
polysaccharide (304). In humans, pneumococcus can cause mild to more severe 
infections, and the asymptomatic nasopharyngeal carriage of pneumococci is 
common (304). The polysaccharide capsule forms the outermost layer of S. 
pneumoniae. Thus far, 91 structurally and serologically different capsular 
polysaccharide types have been recognised (272). The distribution of serotypes 
differs according to age and geographical area, and specific capsule types are 
associated with the capacity to cause severe disease (41). Multiple studies have 
shown that some serotypes and sequence types have a greater invasive potential 
than others (40, 303, 318). Under the thick polysaccharide capsule there is the cell 
wall, consisting of peptidoglycan and teichoic and lipoteichoic acids, which 
contain phosphoryl choline residues as structural components. Teichoic acids are 
linked to the peptidoglycan, whereas lipoteichoic acids are linked to the cell 
membrane (25, 83). In addition, at least three different sets of pneumococcal 
surface proteins are known to anchor to the cell wall: choline-binding proteins, 
peptidoglycan-attached proteins and lipid-attached proteins (25, 172).  
 
In 2001, Tettelin et al. first described the whole genome of a pneumococcal 
serotype (357). Since then, several pneumococcal complete genomes have been 
sequenced, including invasive and non-invasive strains (152, 170, 250). The S. 
pneumoniae genome consist a single circular chromosome with a size ranging 
between 2.03 and 2.24 Mbp, depending on the strain. The average G+C content of 
the pneumococcal genome is 40%. TIGR4, which is a virulent pneumococcal 
isolate, has 2236 open reading frames (ORF), two-thirds of which have assigned 
roles for their predicted gene products. Approximately 20% of ORFs only exist in 
S. pneumoniae. Pneumococci have a large number of insertion sequences, which 
comprise up to 5% of the entire genome (87, 160, 357).  
2.2.2 Diseases and carriage 
Pneumococcus is an important human pathogen causing a wide variety of 
infections. It can cause mucosal infections such as sinusitis and acute otitis media 
(AOM) and  severe invasive infections such as septicaemia, meningitis, 
pneumonia, arthritis, pericarditis and peritonitis (263).  
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Invasive pneumococcal disease (IPD) is most frequent in children less than 2 
years of age, adults aged at least 65 years, and in immunocompromised 
individuals. Each year, 1 million children younger than 5 years of age die from 
pneumococcal diseases, mostly in African and Asian countries (261). Before the 
year 2000, S. pneumoniae infections annually caused approximately 60 000 cases 
of invasive diseases, including 3300 cases of meningitis in the US. The incidence 
of sterile-site infections varied from 21 to 33 cases per 100 000 population. 
However, since the introduction of the 7-valent pneumococcal conjugate vaccine 
(PCV7) in 2000, the incidence of IPD has declined, and in 2002 the incidence of 
invasive disease was 13 cases per 100 000 population in the US (48, 286). In 
developed countries, during 1995–2006, mortality from invasive pneumococcal 
diseases ranges from 5% to 30%, depending on age, genetic background, 
geographical location and the underlying medical condition, but mortality can be 
as high as 50% in Africa (35, 48, 168, 176, 190, 303). The risk factors for IPD are 
presented in Table 1. In addition, a recently published study has demonstrated that 
asthma increases the risk of invasive pneumococcal infections (189). 
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Table 1. Risk factors for pneumococcal pneumonia and invasive pneumococcal 
disease. Adapted and modified from (378). 
 
Definite risk factorsa 
(high risk) 
Probable risk factorsb 
(moderate risk) 
Possible risk factorsc 
(low risk) 
<2 years or >65 years Genetic polymorphisms 
of the host  
Recent exposure to 
antibiotics 
Asplenia or hyposplenia Isolated populations Defects in cellular 
immunity and 
neutrophil defects 
Alcoholism Poverty, crowding, low 
pneumococcal vaccine 
use 
Diminished cough 
reflex, aspiration 
pneumonitis 
Diabetes mellitus Cigarette smoking Proton-pump inhibitors 
and other gastric-acid 
inhibitors 
Antecedent influenza Chronic lung disease Large organism burden 
in upper airways 
Defects in humoral 
immunity (complement 
or immunoglobulin) 
Severe liver disease Child day care  
 
HIV infection Other antecedent viral 
infections 
 
 
Recent acquisition of a 
new virulent strain 
 
Poor mucociliary 
function 
 
 
a Many clinical studies 
b Some clinical and laboratory studies 
c Few clinical studies 
 
In Europe, most of the northern countries have extensive surveillance systems for 
IPD. In 2007, the reported incidence of IPDs was 21 cases/100 000 in Norway and 
16/100 000 in Sweden (91). In Sweden, the reported IPD cases ranged from 1330 to 
1790 cases per year during 2005–2009 (338). In Finland, during 1995–2002, the 
overall annual incidence of IPD was 10.6 per 100 000 persons (188). In addition, 
according to the International Circumpolar Surveillance System for invasive 
pneumococcal disease, the crude annualised incidence of IPD was 12.9 cases per 
100 000 persons during 2000–2005 in Finland (39). S. pneumoniae is the fourth 
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most common blood culture finding in Finland (358). The annual number of new 
invasive (from blood or cerebrospinal fluid (CSF)) S. pneumoniae cases in Finland 
increased from 589 in 1997 to 926 in 2008 (Figure 5). However, the situation 
improved slightly in 2009 and 2010, when 854 and 836 cases were registered, 
respectively (359).  
 
 
Figure 5. Number of S. pneumoniae blood/CSF cases and incidence/100 000 
inhabitants in Finland during 1997–2010 (359). 
 
S. pneumoniae is the most common cause of community-acquired pneumonia (6). 
Outbreaks of pneumococcal pneumonia can occur in crowded institutional settings, 
such as day care centres, nursing homes, military forces and men’s shelters, and 
within urban neighbourhoods (70, 121, 301). Several risk factors have been 
recognised for pneumococcal pneumonia and invasive pneumococcal disease (Table 
1) (190, 219, 378). In Finland, the total annual incidence of pneumococcal 
community-acquired pneumonia among children and the elderly (%60 years) was 
estimated at 6.4/1000 and 8/1000 population, respectively (146, 177).  
    
Acute otitis media (AOM) is one of the most common infectious diseases among 
young children in the developed countries, causing a considerable cost burden to the 
health care system (198, 253). According to a Finnish study, 42% of children have 
had one episode of AOM by one year of age and 71% by two years of age (5). It has 
been estimated that approximately 250 000 AOM episodes occur annually among 
children under 5 years of age in Finland (314). S. pneumoniae is still the major 
bacterial pathogen causing AOM infections, identified in 26–60% of AOM cases 
worldwide (132, 186, 298).  
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Antibiotic resistance in S. pneumoniae strains has become a major public health 
issue. According to data from the European Antimicrobial Resistance Surveillance 
Network (EARS-Net), 7% of the invasive S. pneumoniae isolates reported by 27 
European countries were non-susceptible to penicillin in 2009. High levels (above 
25%) of invasive penicillin-non-susceptible S. pneumoniae were mainly reported 
from southern and eastern Europe, while most of the northern countries reported low 
levels, below 5% (89). However, in Finland, erythromycin and penicillin non-
susceptibility increased from 16% to 28% and from 8% to 16%, respectively, among 
pneumococcal isolates recovered from blood and cerebrospinal fluid samples 
between 2002 and 2006 (331).  
 
The proportion of penicillin- and macrolide-resistant pneumococcal strains causing 
AOM has been estimated to be between 30% and 70% globally (210). However, 
after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7), a 
decline in the incidence of invasive pneumococcal infections and in the rates of 
antibiotic resistance was detected in the US (31, 74, 203, 387). In addition, PCV7 
has been reported to reduce the number of pneumococcal AOM episodes in the US 
and also in Finland (46, 101, 108). Several studies have demonstrated a reduction in 
the carriage of 7-valent pneumococcal conjugated vaccine serotypes and 
replacement by non-vaccine serotypes (74, 150, 273). An increase in the incidence 
of pneumococcal disease caused by non-PCV7 serotypes has also been observed (9, 
45, 150, 215).  
 
S. pneumoniae can colonise the nasopharyngeal niche of healthy children and adults. 
Colonisation typically leads to asymptomatic carriage, although in some cases 
colonisation is followed by disease (33). Pneumococcal carriage starts during the 
first months of life and is highest among young children (33, 125, 349). The 
pneumococcal carriage rate of healthy children varies widely from 2% to 70% (28, 
34, 60, 350). In Finland, the carriage of S. pneumoniae in healthy children younger 
than 2 years of age was reported to vary from 9 to 43%, and increased gradually 
with age (349). The proportion increased during respiratory infections without AOM 
to 22–45%, during AOM to 45–56%, and during pneumococcal AOM almost every 
children carried S. pneumoniae in the nasopharynx (97–100%) (349). The 
pneumococcal serotypes found in the middle ear and in the nasopharynx are usually 
the same (93, 389). Pneumococcal infection is usually caused by one serotype, 
which is acquired only shortly before the infection. However, during pneumococcal 
carriage, the sequential acquisition of more than one serotype is common (125, 263, 
348). The common risk factors for pneumococcal carriage are ethnicity, crowding, 
environmental features and socioeconomic features. Environmental and 
socioeconomic risk factors include family size, income, smoking and recent 
antibiotic use (33). In addition, a recent study demonstrated that asthma can be a 
significant risk factor for pneumococcal carriage (178). 
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2.2.3 Virulence factors and pathogenesis 
 
Pneumococcal infection is a complex interplay between virulence factors of the 
infecting strain and the host defence system. The pneumococcus produces a range of 
factors (colonising and virulence) that are involved in the disease process. The 
pathogenic route of S. pneumoniae infection is presented in Figure 6. 
 
 
 
Figure 6. Pathogenic route of S. pneumoniae infection. Adapted from (33).  
 
Pneumococcal disease usually occurs with preceding nasopharyngeal colonisation 
with a homologous strain (104, 125). Several pneumococcal adhesins are involved 
in the process of adhesion to human cells. Invasion of the lower respiratory tract is 
an important event in pneumococcal infection, which may lead to bloodstream 
invasion (118). To cause meningitis, blood-borne bacteria must localise in and cross 
the blood-brain barrier (199, 294). In addition to capsular polysaccharides, multiple 
virulence factors contribute to invasive disease. Some successful clones may have 
gathered a collection of genes providing a selective advantage in the invasion 
process (118). 
 
By preventing phagocytosis, the polysaccharide capsule is the most important 
pneumococcal virulence factor (364). The capsule is also crucial in colonisation and 
dissemination from the respiratory tract. It can prevent mechanical removal by 
mucus, inhibit autolysis and reduce exposure to antibiotics (251, 378). Pneumococci 
are able to exchange their capsular type through horizontal recombination of 
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pneumococcal DNA surrounding the capsular loci by natural transformation (11, 57). 
Capsular switching most presumably occurs during nasopharyngeal carriage, when 
intermixing of clones expressing different types of capsular polysaccharides is 
possible (57, 279).   
 
The pneumococcal exotoxin pneumolysin is a pore-forming cytotoxin that is 
expressed by almost all invasive pneumococcal strains. Pneumolysin is the most 
extensively studied pneumococcal protein virulence factor. It has been shown to 
have several roles in infection, including its ability to activate complement, lyse the 
host cells, induce the production of chemokines and cytokines, activate CD4+ T 
cells, impair the respiratory burst of phagocytic cells, and activate inflammation 
(158, 237, 378, 404).  
 
The roles of several LPXTG-anchored surface proteins in virulence have been 
investigated, including hyaluronidase and neuraminidase. Hyaluronidase degrades 
hyaluronic acid in the mammalian connective tissue and extracellular matrix, and 
may aid bacterial spread and colonisation (171, 237).  Neuraminidase may cause 
direct damage to the host cell or it may unmask potential binding sites for the 
organism by cleaving the N-acetylneuraminic acid from compounds such as mucin, 
glycolipids, glycoproteins, and oligosaccharides on cell surfaces and in body fluids, 
contributing to increased adhesion and invasion (43, 171, 362, 367).   
 
Some of the pneumococcal surface proteins are directly attached to the lipids of the 
bacterial cytoplasmic membrane. Pneumococcal surface antigen A (PsaA) is a 
surface-exposed multi-functional lipoprotein. It mediates metal ion uptake by acting 
as a part of an ATP-binding cassette (ABC)-transporter. It is also an adhesin that 
plays major roles in pneumococcal colonisation and virulence (289). Two surface-
exposed lipoprotein peptidyl prolyl isomerases, SlrA and PpmA, have also been 
demonstrated to have a role in virulence and colonization (69, 148). In addition, 
PpmA has been shown to be immunogenic in humans (370). PiaA and PiuA are 
lipoproteins that are also involved in virulence by acting as components of two 
separate iron-uptake ABC transporters (386).  
 
Choline-binding proteins (CBPs) are attached to the pneumococcal cell surface via 
terminal choline residues of teichoic/lipoteichoic acids that are present on the 
surface of the bacteria. Several CBPs have been demonstrated to have a role in 
virulence, including cell wall hydrolytic enzymes such as N-acetylmuromyl-L-
alanine amidase (LytA), !-N-acetylglucosamidase (LytB), !-N-acetylmuramidase 
(LytC), and phosphorylcholine esterase (CbpE/Pce), as well as pneumococcal 
surface protein A (PspA) and C (PspC) (29, 124, 171). PspA and PspC are widely 
studied multifunctional virulence factors of pneumococci. PspA has the ability to 
inhibit the alternative pathway of complement activation (293, 363). PspA also 
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binds to lactoferrin, which has an important role in innate immunity (137).  The 
main virulence functions of PspC are its ability to act as an adhesin by binding to the 
polymeric immunoglobulin receptor and to limit opsonophagocytosis by binding the 
complement regulatory protein factor H and blocking C3b fixation (76, 138, 169, 
402).  
 
Several other surface proteins have been identified without any recognised anchor 
motifs, including pneumococcal adherence and virulence factor A (PavA), two 
glycolytic enzymes, glyceraldehyde-3-phosphate dehydrogenase and enolase, and 
the pneumococcal histidine triad protein (Pht) family (237). PavA is an adhesin that 
mediates attachment to endothelial cells by binding to the fibronectin, and it is 
essential for pneumococci to escape phagocytosis (256, 284). Glyceraldehyde-3-
phosphate dehydrogenase and enolase are plasminogen-binding proteins (26, 27). 
The Pht family members have the ability to provide protection against infection 
when used as vaccines (1, 392). In addition, Pht proteins may have a role in 
complement evasion (230, 265).   
 
Recently, adhesive pili have also been reported to exist on the surface of 
pneumococci, referred to as pilus islet 1 (PI-1) and 2 (PI-2) (13, 17). The rlrA 
pathogenicity islet, coding for PI-1 genes, was already identified in  a genome-wide 
screen in 2003 (143). The pneumococcal rlrA pathogenicity islet includes three 
structural protein genes (rrgA, rrgB, and rrgC), three genes coding for sortase 
enzymes (srtB, srtC, and srtD) responsible for linking structural subunits, and the 
rlrA gene coding for a positive regulator of rlrA pathogenicity island genes. The 
gene cluster is flanked by insertion sequences characteristic of a mobile element 
(143) (Figure 7). The three genes coding for structural proteins (rrgA, rrgB, and 
rrgC) have homology to the LPXTG family of cell wall-anchored surface proteins 
(143). 
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and a gene for a positive regulator (rlrA). IS1167/IS1167’ codes for insertion 
sequences of the rlrA pathogenicity islet. Adapted from (143). 
 
Sequence comparison of 15 rlrA islets revealed the presence of 3 clade types, with 
an overall similarity of 88–92% (243). The molecular architecture of PI-1 has been 
identified. The native pili are flexible filaments that can be approximately 6 nm wide 
and over 1 µm long, consisting of a shaft composed of RrgB monomers, with RrgA 
at its distal and RrgC at its proximal end. It has been suggested that RrgC anchors 
the pilus to the peptidoglycan cell wall and RrgA has a role as an adhesin (153, 154).
 
PI-2 codes for a second functional pilus in pneumococcus between flanking 
sequences pepT and hemH (13). PI-2 consists of two structural protein genes (pitA 
and pitB), two sortase genes (srtG1 and srtG2) and a gene coding for putative signal 
peptidase (sipA) (Figure 8) (13). Sequence alignment of nine PI-2s defined an 
overall similarity of approximately 99% (13).  
  
 
 
Figure 8. Schematic presentation of PI-2. The locus includes two sortase genes 
(srtG1 and srtG2), two pilus subunit genes (pitA and pitB) and a gene for a putative 
signal peptidase (sipA). hemH and pepT are the flanking sequences of the locus. 
Adapted from (13). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic presentation of the rlrA pathogenicity islet. The locus includes 
three sortase genes (srtB, srtC, srtD), three surface protein genes (rrgA, rrgB, rrgC) 
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Both these pilus islets seem to be present in some, but not all, clinical isolates. In 
addition, some strains are capable of expressing both PI-1 and PI-2 (13). Moreover, 
the isolates harbouring pilus islets are variable in terms of serotypes and genotypes. 
The prevalence of PI-1 varies from 21% to 30.6% among invasive and non-invasive 
isolates (2, 18, 242, 243). PI-1 has been reported to correlate with the pneumococcal 
genotype rather than the serotype (2, 242). In addition, a recent study demonstrated a 
correlation between PI-1 and antibiotic resistance (242). In murine models of 
pneumococcal infection, PI-1 has been shown to be involved in adherence to 
epithelial cells and virulence (17). The prevalence of PI-2 has been identified to be 
21% among invasive isolates, 16% among both invasive and nasopharyngeal 
isolates, and 7% among MEF isolates (13, 242, 406). PI-2 has been shown to play a 
role in adherence to epithelial cells (13). 
 
Pneumococcus requires genetic variability, adaptability and modulated expression of 
virulence factors to be able to survive and succeed in different host 
microenvironments. S. pneumoniae is one of the bacterial species having the ability 
to take up DNA from the external environment (natural genetic transformation)(11) 
and incorporate it into their genomes by homologous recombination (144). 
S. pneumoniae is competent (a state in which cells are able to take up free DNA) for 
only a short time period, and most probably regulates the expression of genes 
encoding competence proteins in response to certain cellular and/or environmental 
signals (174). Natural genetic transformation allows pneumococci to take up DNA 
from other S. pneumoniae and closely related streptococcal species. In addition, 
there is recent evidence that S. pneumoniae does not only rely on the accidental 
release of DNA for transformation but can trigger active release. The release 
involves a killing mechanism that could be used by competent cells to acquire DNA 
from non-competent (a state in which cells are not able to take up free DNA) 
pneumococci. This phenomenon is termed pneumococcal fratricide (145). In 
fratricide, the competent cells express a set of murein hydrolases (LytA, CbpD, and 
LytC) that attack the cell wall of non-competent target cells, resulting in cell lysis 
and the release of DNA, which can be taken up by competent cells (174). Through 
this behaviour, pneumococci can gain access to transforming DNA and nutrients, 
promote the release of virulence factors and kill competitors (145). Capsular 
switching of pneumococci is one of the known consequences of pneumococcal 
genetic transformation (57). It has recently been shown that killing is not limited to 
S. pneumoniae, but that related species such as Streptococcus mitis and 
Streptococcus oralis can also be attacked by competent pneumococci (173).  
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2.3 Bacterial typing 
2.3.1 Reasons for bacterial typing 
Bacterial typing methods are used as means to study the spread and population 
dynamics of bacteria in clinical and environmental settings. There are several 
reasons for typing bacteria for epidemiological purposes. Typing methods contribute 
essential information to epidemiological surveillance of infectious diseases. 
Surveillance is defined as an ongoing systematic process of data collection, analysis 
and interpretation of data, and dissemination of results, to be able follow disease 
trends and design ways to fight them (344, 375). Typing is an important tool for 
infectious disease outbreak investigations, where the aim is to define a local and 
temporal increase in the incidence of infection by a certain bacterial species. The 
typing of outbreak strains facilitates the development of outbreak control strategies, 
defining of the extent of epidemic spread of bacterial clones and the number of 
clones involved in transmission and infection, monitoring of the reservoirs of 
epidemic clones, and control evaluations of the efficacy of control measures, such as 
monitoring vaccine efficacy (344, 375, 380). By using typing methods, distinct 
epidemiological markers associated with pathogenic isolates can be detected (380). 
As an example, the presence of the gene coding for PVL in S. aureus strains is 
speculated to be linked to severity of necrotising pneumonia in young patients (119). 
Some molecular typing methods may be applied to study bacterial populations, 
evolution and the phylogenetic relationships between species (221, 375). 
2.3.2 Criteria for evaluation, validation and comparison of typing 
methods 
Several criteria should be considered when evaluating, validating and comparing 
typing methods. These can be divided into performance and convenience criteria 
(Table 2). The selection of the optimal and most applicable typing method depends 
on the purpose of the analysis (110, 332, 344, 374, 375). After the typing method 
has been selected, it is very important to carefully match this technology with the 
speed at which the molecular changes occur (374). The use of typing tools in 
epidemiological studies requires understanding of both the strengths and limitations 
of the chosen typing method as well as the epidemiological study design to be able 
to address the research question (110, 346). In addition, laboratory and 
epidemiological evidence validate each other, and typing results must therefore be 
interpreted in the context of the epidemiological evidence as well as the 
characteristics of the bacteria (110). To enable comprehensive epidemiological 
surveillance and international comparability, often one typing method alone is not 
sufficient, and a combination of various molecular typing techniques is used (86, 
231, 388).  
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2.3.3 Characteristics of typing methods 
Typing methods can be classified into phenotyping and genotyping methods. 
Phenotyping techniques detect the characteristics expressed by bacteria, while 
genotyping methods assess the variation in the chromosomal or extrachromosomal 
nucleic acid composition of bacterial isolates (375, 380). Phenotyping involves 
methods for detecting differences in biochemical reactions, morphology, and the 
environment. Biotyping is a widely used phenotyping method to assess biochemical 
characteristics varying within a given species, and is usually used in diagnostics and 
species identification and to separate the members of a particular species (332). 
Other commonly used phenotyping methods include serotyping, antimicrobial 
susceptibility testing, and bacteriophage and bacteriocin typing. Less frequently 
used phenotyping methods include multilocus enzyme electrophoresis (MLEE), 
mass spectrometry (MS) and SDS-PAGE of cellular and extracellular components 
(332, 375, 380).   
 
Different genotyping methods are likely to reveal different degrees of genetic 
variability. Genetic diversity arises by various molecular processes, including the 
accumulation of spontaneous point mutations, diverse types of genetic 
rearrangements, and the loss and acquisition of chromosomal and extra-
chromosomal DNA sequences (380). Genotyping methods define variation in the 
genomes of bacterial isolates with respect to the composition, overall structure, or 
precise nucleotide sequence. The increasing availability of bacterial genome 
sequences has had a significant impact on the evolution and improvement of 
genotyping methods (375).  
 
Bacterial genotyping methods can be classified into three main categories: 
hybridisation-mediated, fragment-based and sequence-based methods (375). 
Hybridisation-mediated methods include ribotyping, which has been used for a long 
time, and novel DNA array-based methods such as DNA macro- and microarrays, 
cDNA microarrays and oligonucleotide microarrays (129, 375). Fragment-based 
methods can be separated into methods where fragments are generated by cleavage 
of DNA using restriction enzymes, including methods such as plasmid typing, 
restriction fragment length polymorphism (RFLP), restriction endonuclease analysis 
(REA), and pulsed-field gel electrophoresis (PFGE) (149, 225, 270). PCR 
fingerprinting (e.g. BOX, arbitrarily primed PCR), repetitive sequencing-based PCR 
(REP-PCR), and multilocus variable number tandem repeat analysis (MLVA) (217, 
373, 375) are fragment-based methods where fragments are generated by 
amplification of DNA. A combination of both restriction enzyme digestion and 
DNA amplification includes methods such as PCR-RFLP and amplified fragment 
length polymorphism (AFLP) (375, 394). Sequence-based methods include single-
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locus sequence typing (SLST), multilocus sequence typing (MLST), single 
nucleotide polymorphism (SNP) genotyping and genome sequencing, which is 
currently still too expensive and time demanding to be used in routine genotyping 
(213, 222, 375, 380).     
 
The interpretation of typing data is an important phase in the typing process. 
Depending on the typing method, the interpretation of the experimental data leading 
to correct identification can be complicated and demanding. This may be due to 
technical factors relating to the typing method used or the fact that an epidemic 
strain can evolve during an ongoing outbreak (380). Some typing methods are more 
stable than others. For example, PFGE patterns of MRSA strains have been 
demonstrated to be relatively stable over periods of weeks to months (32). However, 
the use of PFGE in long-term laboratory-based surveillance can be misleading (351, 
353). Interpretation rules should provide well-defined guidelines for unambiguous 
data interpretation, whether the strain is unique or a part of an outbreak (352, 353). 
Although computer-assisted analysis is nowadays common, most image-based 
methods generate complex band patterns, the interpretation of which remains 
subjective. Sequence-based typing methods allow unambiguous data interpretation, 
and therefore also better international comparison (100, 140, 222). 
 
International databases are nowadays extremely important due to the worldwide 
spread of bacterial clones. Such databases rely on standardised typing methods and 
quality control ring trials for all participating laboratories. Significant efforts have 
been made to harmonise typing methods of multiple bacteria at the international 
level and to establish a standardised nomenclature (3, 218, 247, 276). There are 
several international databases, servers and networks to ease the comparison of 
typing data. These help in local infection control, as well as national and 
international surveillance of bacteria. Sequence-based methods, such as MLST of 
several different bacteria and spa typing of S. aureus, have useful international 
databases, MLST.net and SeqNet.org (SpaServer), respectively (238, 326). PulseNet 
for different foodborne pathogens and SalmGene for Salmonella species are 
molecular epidemiology databases with typing data and information concerning the 
clinical and/or epidemiological features associated with the isolates analysed. There 
are several different laboratory networks that base the strain comparison on PFGE 
methods, including PulseNet, SalmGene, HARMONY for S. aureus, and Listernet 
for L. monocytogenes (63, 79, 287, 313, 375). 
 
The typing methods used in this thesis are discussed in more detail below. 
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2.3.4 Serotyping 
Serotyping is a classic and important phenotyping method that has been developed 
since the early days of microbiology and successfully used for taxonomic grouping 
and epidemiological studies on a number of bacterial species. Serotyping is still 
important for typing Salmonella, Legionella, Shigella and S. pneumoniae. 
Traditionally, serotyping uses a series of antibodies to detect antigens on the surface 
of the bacterial cell. There are many ways in which serotyping can be performed and 
antibody-antigen reactions detected. Direct antibody-antigen agglutination is a 
frequently used method in which a bacterial cell suspension is mixed with panels of 
antibodies and the serotype is determined according to the agglutination profiles 
(332, 375). In addition, different types of molecular serotyping methods have been 
developed (37, 340). 
 
Serotyping continues to be a valuable typing technique for S. pneumoniae, 
especially in monitoring vaccine efficacy and detecting the emergence of non-
vaccine strains. The standard method for pneumococcal serotype determination has 
been the Quellung reaction, in which test antibodies bind to the corresponding 
capsular antigens and induce swelling of the capsule, which can be observed with 
light microscopy (186, 339). Several alternative methods to the capsular reaction test 
have been described for serotyping pneumococci, including a latex agglutination test, 
slide-agglutination method, a latex bead-based cytometric immunoassay, 
counterimmunoelectrophoresis (CIEP), enzyme-linked immunosorbent assay 
(ELISA), and recently a number of DNA techniques (37, 147, 224, 244, 271, 337, 
384). PCR-based serotyping methods using primers that amplify serotype-specific 
genes coding for the capsule have been demonstrated, such as multiplex PCR-based 
serotyping, real-time PCR serotyping, PCR-based reverse line-blot hybridisation 
serotyping, and PCR restriction fragment length polymorphism (RFLP) (19, 37, 47, 
194, 384). In addition, for S. pneumoniae serotyping, microarray analysis and few 
sequence-based assays have been described (21, 195, 196).    
2.3.5 Antimicrobial susceptibility testing 
Clinical microbiology laboratories commonly perform antibiotic susceptibility 
testing, providing important information for a clinician to choose the optimal 
antimicrobial treatment for a patient. Susceptibility testing results are also used in 
surveillance studies and by infection control personnel to detect and control the 
spread of antibiotic-resistant organisms (307, 308). In addition, antibiograms can be 
used as a typing method. Antimicrobial susceptibility testing can be performed by 
using either disk diffusion or broth microdilution methods with a variety of 
measurements systems. Susceptibility testing can measure the minimum inhibitory 
concentration (MIC) of an antimicrobial agent that prevents bacterial growth (in 
mg/L or µg/ml), or the test can provide qualitative results, as in the disk diffusion 
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method, categorising bacteria into three susceptibilities: susceptible (S), intermediate 
(I), and resistant (R) (365). To interpret an antibiogram, breakpoints for the separate 
susceptibility categories need to be determined. Many organisations such as the 
Clinical Laboratory Standards Institute (CLSI) and European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) have worked to standardise and 
harmonise antimicrobial susceptibility testing protocols and breakpoints (56, 102).  
 
Discrimination in antibiogram-based typing is dependent on the diversity, stability 
and relative prevalence of resistance mechanisms of the study isolates (375). In most 
epidemiological studies, antibiogram-based typing has relatively limited value due 
to its poor discriminatory power (352). In addition, antimicrobial resistance is often 
associated with mobile genetic elements (e.g. transposons and plasmids) that are 
rather instable and under selective pressure. Therefore, isolates that are not 
genetically and epidemiologically related may have the same susceptibility pattern. 
Resistance characteristics have been used to characterise certain global MRSA 
clones and to distinguish CA-MRSA and HA-MRSA, in addition to other typing 
methods (382, 390). However, the separation of CA-MRSA and HA-MRSA based 
on the antibiotic phenotype is becoming more problematic due to the migration of 
CA-MRSA into healthcare settings and the recent increasing antibiotic resistance of 
CA-MRSA strains (226).       
2.3.6 Virulence gene detection and typing based on the polymerase 
chain reaction (PCR)  
The polymerase chain reaction (PCR) was first described by Saiki et al. in 1985 and 
Mullis and Faloona in 1987 (245, 309). PCR is an in vitro reaction where a targeted 
nucleic acid sequence is amplified by using oligonucleotide primers, thermostable 
DNA polymerase, deoxynucleoside triphosphates (dNTPs), divalent cations (usually 
Mg2+), a buffer to maintain the pH, monovalent cations (KCl), and template DNA 
(316). A large number of variations on the method have been described. In multiplex 
PCR, two or more primer sets are designed for the simultaneous amplification of 
different target DNA in a single reaction tube, which increases the efficiency of PCR 
and reduces the reagent costs (51, 255, 332). Real-time PCR amplifies and detects 
the target DNA sequence in real time and simultaneously by using specific dyes and 
fluorescent measurements (201, 391).   
 
Conventional, real-time, and multiplex PCR methods have been used to detect 
virulence factors (pathotypes) from a variety of bacterial isolates and clinical 
specimens for different purposes. PCR-based virulence gene detection has been used, 
for instance, for species identification and to detect distinct virulence markers 
associated with pathogenic isolates within a species (8, 14, 214, 328).  
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PCR techniques are widely used in the identification of multiple S. aureus virulence 
factors, to determine the distribution of virulence factors among S. aureus strains, 
the relationship between the genetic background of S. aureus, and the association of 
virulence factors with certain forms and the severity of certain disease (380). Several 
PCR assays have been developed to detect PVL, a necrotising cytotoxin of S. aureus 
that has been associated with necrotic lesions of the skin and subcutaneous tissues 
and severe necrotising pneumonia (4, 204, 214, 227). PCR techniques have also 
been used to identify several other virulence factors of S. aureus, such as 
enterotoxins, exfoliative toxins, TSST-1 and different adhesin genes (211, 240, 405).  
 
To date, several structural differences in SCCmec elements of S. aureus have been 
identified (167). The typing of SCCmec is used in epidemiological studies to 
discriminate MRSA strains or to define an MRSA clone in combination with the 
genotype (sequence type) (320, 346). In addition, SCCmec typing is used for 
evolutionary studies on MRSA (81). SCCmec types can be detected by identifying 
specific genes or gene alleles that are required for classification by PCR. Typically, 
first the type of ccr and class of mec are determined, and SCCmec types can then be 
subtyped by investigating differences in J regions. Multiplex PCR is usually used to 
assign ccr types, mec classes and J regions (320). 
 
Pneumolysin is the most frequently applied virulence factor for pneumococcal 
identification and has been used to demonstrate pneumococcus directly from blood, 
cerebrospinal fluid, serum, pleural fluid, middle ear fluid, and a nasopharyngeal 
specimen (205, 315, 319, 379, 389). In addition, various other pneumococcal 
virulence factors have been demonstrated by using PCR, such as autolysin (LytA) 
and PsaA (235, 328). Pilus islets 1 (PI-1) and 2 (PI-2) have been shown to be 
involved in the virulence of pneumococcus, and the prevalence of PI-1- and PI-2-
genes has been determined by PCR in multiple studies (2, 13, 18, 242, 243, 406).  
2.3.7 Pulsed-field gel electrophoresis (PFGE) 
Pulsed-field gel electrophoresis (PFGE) is an electrophoretic method used to 
separate large DNA molecules ranging from 10 kbp to 10 Mbp after rare-cutting 
restriction enzyme digestion of the total genomic DNA. PFGE can separate large 
DNA molecules due to an alternating electrical field at different angles in a flat 
agarose gel (149, 213, 323). Random genetic events including deletions, insertions 
and point mutations can alter the restriction sites and affect the banding pattern of 
the strain. PFGE was originally used for electrophoretic separation of the 
chromosomes of lower eukaryotes, and is now considered as a valuable typing tool 
for a wide variety of bacterial species such as S. aureus, S. pneumoniae, C. difficile, 
Streptococcus group A and B, and foodborne pathogens such as enterohaemorrhagic 
Escherichia coli (EHEC), Salmonella, Shigella, Listeria and Campylobacter (63, 
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288, 323, 353, 375). PFGE is still considered a successful typing method due to its 
high discriminatory power and reproducibility (110, 346, 352). However, it has 
some shortcomings, as it is a technically demanding, low-throughput and slow 
method, the interpretation of band profiles is subjective and interlaboratory 
comparison of strain profiles is difficult (346).    
 
PFGE has been the ‘gold standard’ genotyping method for MRSA for over a decade, 
and it has been used widely for local outbreak investigation, long-term surveillance 
of MRSA infections at regional and national levels and for international 
comparisons (346). In Europe, harmonisation efforts have been made to standardise 
the PFGE typing protocol of MRSA and enable multicentre comparison of PFGE 
data (54, 247). Although PFGE has been valuable and the main typing method for 
MRSA for long time, weaknesses including the technical aspects, misleading 
interpretation in long-term epidemiological investigations, and the emergence of 
non-typeable isolates (e.g. livestock-associated ST398) have reduced the use of 
PFGE typing for MRSA (346, 351, 353).  
  
PFGE is also a widely applied genotyping method for S. pneumoniae, and has been 
used to subtype, compare and characterise certain pneumococcal serotypes such as 
vaccine serotypes, vaccine-related serotypes, non-vaccine serotypes, and penicillin-
resistant and penicillin-non-susceptible serotypes (86, 88, 116, 264). In addition, 
studies such as analysis of the genetic relatedness of pneumococcal isolates from 
paired blood and respiratory specimens, and comparison of pneumococcal 
nasopharyngeal isolates have used PFGE for characterising of the isolates (141, 399). 
Moreover, PFGE can be used to determine invasiveness and to differentiate 
pneumococcal clones (264). 
2.3.8 Single-locus sequence typing (SLST) 
Single-locus sequence typing (SLST) is a term for a variety of typing methods in 
which the sequencing of a single genetic locus provides useful typing results. To be 
able to provide sufficient discriminatory power, the target locus for SLST must be 
highly variable (375). SLST methods are rapid, easy to use and have high 
throughput, discriminatory power and reproducibility. The typing results of SLST 
are accurate, unambiguous and easily comparable (110, 332, 346).     
 
One of the epidemiologically significant SLST schemes is emm typing of S. 
pyogenes, which is regarded as the ‘gold standard’ method for genotyping of 
streptococci. It is based on the sequencing of a 180 bp part of the hypervariable 5’ 
terminus of the emm gene (103). At present, more than 100 emm sequence types and 
an even higher number of subtypes have been identified and stored in the database 
(49).   
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spa typing is a reliable tool for typing S. aureus and has become the most popular 
MRSA typing method (346). The method is based on sequencing of the polymorphic 
X region of the protein A gene (spa), present in nearly all S. aureus strains. The X 
region comprises of a variable number of typically 24 bp repeats flanked by well-
conserved regions (Figure 9) (111, 112). The variable number of tandem repeats 
(VNTR) structure of the X region of the spa gene is explained by the slipped strand 
mispairing model. According to this model, illegitimate basepairing due to stretches 
and loops in short repeated unit motifs occurs during DNA replication, which leads 
the DNA polymerase to delete or insert repeat units (372). Many studies have 
evaluated the usefulness of spa typing for diverse epidemiological purposes and 
confirmed its ease of use, speed, high discriminatory power, reproducibility and 
typeability, and the portability of results (3, 135, 197, 329, 343, 351). In addition, 
due to the repeat structure, the spa gene characterises micro- and macrovariations, 
enabling the use of spa typing in both long- and short-term epidemiological studies, 
locally and globally (136, 197, 375). However, because spa typing is based on DNA 
sequences in hypermutable regions, it should be noted that mutants may arise even 
during an outbreak and therefore falsely suggest that the outbreak has multiple 
sources rather than one (375). Related spa types can be clustered (spa CC) according 
to the repeat structure by using the based upon repeat pattern (BURP) algorithm, 
which takes into account duplication and excision of the repeats (232). spa typing is 
suitable for computerised analysis, and at least two commercial software packages 
are currently available for spa typing (136). In addition, standardised nomenclature 
and Internet shared database (SpaServer) support and facilitate the use of the method 
(140, 326). The central spa server is organised by the SeqNet.org typing network, 
which currently includes 45 laboratories from 25 European countries (113).   
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Figure 9. (a) Schematic diagram of the spa gene. S is the signal sequence; A to D are 
IgG-binding domains, E is a region homologous to A-D, X is the C-terminal part, 
divided into two regions, the VNTR region (Xr) and a constant region coding for 
cell wall attachment (Xc). (b) The repeat structure of the Xr region. The spa type 
presented is t067. (c) The DNA sequence of spa repeat 17. Adapted and modified 
from (136). 
* SpaServer accessed July 2011.  
2.3.9 Multilocus sequence typing (MLST) 
Multilocus sequence typing (MLST) compares the nucleotide sequences of internal 
400- to 500-bp regions of a series of housekeeping genes (usually five to ten), which 
are present in all isolates of a particular species (100, 222). For each gene fragment, 
the different sequences are assigned to distinct allele identification numbers and the 
combination of the numbers defined for all alleles generates the sequence type (ST). 
Isolates that have the same allelic profile can be considered as members of the same 
clone. The eBURST (based upon related sequences) program is used to cluster STs 
into clonal complexes (CC). The algorithm behind the program assigns the central 
genotype of CCs, which is the one with the highest number of single-locus variants 
(SLVs) (107). MLST has been applied to a large number of bacterial species (221, 
238). It is useful tool for epidemiological analysis and surveillance of pathogens, 
and especially to study their population structure and evolution (221). MLST may be 
a more significant tool for population genetics and dynamics than for bacterial 
epidemiology, since its targets are the slowly evolving housekeeping genes. MLST 
has standard nomenclature and the data generated are fully portable both within and 
between laboratories. MLST data are available and can be shared globally via the 
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Internet (238, 285). However, MLST also has some drawbacks. It often fails to 
detect the variability of closely related strains and thus has only moderate 
discriminatory power. In addition, sequencing of several genes is time-consuming 
and costly (346).  
 
MLST is particularly suitable for subtyping bacterial species with high a rate of 
genetic recombination, such as S. pneumoniae and N. meningitidis (99, 222). More 
than 5000 different allelic profiles are currently available for S. pneumoniae in the 
MLST database (238, 285). MLST has been used to identify antibiotic-resistant 
clones and virulent clones of pneumococcus causing invasive diseases (99, 117, 206, 
331). MLST has been applied in research on S. aureus for ten years, and has been 
extremely useful for understanding the population structure of the species (96, 98). 
To date, more than 1700 MLST-based STs of S. aureus have been reported on the 
MLST website (238). MLST has been also used in several studies to understand the 
evolution of MRSA (95, 96, 98, 258, 269, 296). All major MRSA and MSSA clones 
are named according to their MLST and staphylococcal cassette chromosome 
(SCCmec) types (98). Some MRSA clones are associated with CA-MRSA or HA-
MRSA infections (44, 98, 106, 381). In addition, several pandemic MRSA clones 
have also been described (95, 269). 
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3 AIMS OF THE STUDY 
The general purpose of this thesis was to characterise two medically important 
bacterial pathogens, methicillin-resistant Staphylococcus aureus (MRSA) and 
Streptococcus pneumoniae, in detail by using several molecular typing methods for 
various epidemiological purposes: clonality analysis, epidemiological surveillance, 
outbreak investigation, and virulence factor analysis.  
 
The specific objectives of this study were: 
 
1. To evaluate the typeability, discriminatory power, and concordance of different 
genotyping methods of epidemic MRSA in determining the characteristics and 
clonality of strains for epidemiological surveillance and outbreak investigations of 
MRSA in Finland (I). 
 
2. To search for a rapid typing scheme for national surveillance, epidemiological 
investigations and international comparisons of MRSA in Finland and to 
characterise Finnish MRSA isolates in more detail (II).  
 
3. To study the cause and extent of a pneumococcal pneumonia outbreak among 
military recruits in Finland, and to define the pneumococcal carriage rate and 
molecular characteristics of the detected S. pneumoniae isolates (III).  
 
4. To analyse the prevalence of pilus-encoding islets and the clonality of 
pneumococcal isolates associated with nasopharyngeal carriage and/or acute otitis 
media in children with AOM in Finland, in order to elucidate the association of pili 
with the disease potential of S. pneumoniae in AOM infections (IV).  
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4 MATERIALS AND METHODS  
4.1 Bacterial isolates 
The bacterial isolates used in the different studies are presented in Table 3. Since, 
1995, all clinical microbiology laboratories across Finland have notified all MRSA 
findings in the National Infections Disease Register (NIDR) at the National Institute 
for Health and Welfare (THL). In this register, MRSA notifications concerning 
isolates from blood and cerebrospinal fluid from the same patient within a time 
interval of three months are merged into a single case. Before 2007, MRSA 
notifications from other sources were combined into a single case within a time 
interval of three years, and thereafter the time interval has been 50 years. Clinical 
laboratories send all MRSA isolates, corresponding to the notifications, to the 
Staphylococcal Reference Laboratory at THL for genotyping. MRSA isolates used 
for publication I and II were from the Strain Collection of NIDR. Pneumococcal 
isolates for publication III were isolated from blood and nasopharyngeal samples of 
military recruits of the Finnish Border Guard in the Kainuu Border Guard District 
involved in an outbreak investigation of pneumococcal pneumonia. S. pneumoniae 
isolates for publication IV were collected from MEF and NPA samples of children 
with AOM. Samples were obtained at the initial visit to the Department of 
Otolaryngology of Helsinki University Central Hospital (389).  
 
Control strains used are described under the corresponding typing method.  
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4.2 Epidemiological background data 
For publication III, the epidemiological background data were retrieved by 
interviewing all the military recruits involved in a pneumococcal pneumoniae 
outbreak investigation. The epidemiological background data included the preceding 
symptoms, medical history, medication and smoking habits of the military recruits 
and were collected by a local infection control nurse with informed consent. In 
addition, the medical records of five hospitalised recruits were reviewed.  
 
A confirmed pneumococcal pneumonia case was defined as having a positive blood 
culture for S. pneumoniae, in addition to the signs and symptoms. A non-
bacteraemic pneumonia case was defined as having respiratory symptoms with fever 
and a lobar infiltrate in a chest radiograph. 
 
4.3 Bacterial identification 
All S. aureus isolates suspected of being MRSA and received from clinical 
laboratories were confirmed at the Staphylococcal Reference Laboratory at THL by 
detecting mecA and nuc genes using PCR until 2005. Thereafter, clinical 
microbiology laboratories have identified the isolates as Staphylococcus aureus by 
standard procedures (16) and confirmed methicillin resistance either by detecting the 
mecA gene using molecular methods or by testing oxacillin MIC by Etest 
(BioMérieux, France). According to the Finnish Study Group for Antimicrobial 
Resistance (FiRe), if the oxacillin MIC is above 64 mg/l, detection of the mecA gene 
is not required. 
 
Identification of the pneumococcal isolates was performed in clinical laboratories 
(two isolates from blood for publication III) and in THL (nasopharyngeal swab 
specimens for publication III, isolates from MEF and NPA for publication IV) by 
using conventional methods (304), optochin susceptibility and bile solubility testing. 
 
4.4 Antimicrobial susceptibility testing 
The antimicrobial susceptibility of MRSA isolates was tested according to the 
guidelines of the Clinical and Laboratory Standards Institute (CLSI) (former 
National Committee for Clinical Laboratory standards, NCCLS) (publication I). The 
antimicrobial agents oxacillin, ampicillin, penicillin, cephalexin, cefuroxime, 
gentamicin, tobramycin, erythromycin, clindamycin, chloramphenicol, ciprofloxacin, 
rifampicin, fusidic acid, mupirocin and vancomycin were tested by the disk 
diffusion method. Oxacillin and vancomycin MICs were determined by the E-test 
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(AB Biodisk, Solna, Sweden) according to the recommendations of the 
manufacturer. If the isolates were resistant to three or more antimicrobial agents 
groups, they were considered multiresistant.  
 
MIC testing of pneumococcal isolates was performed by the agar plate dilution 
technique. The antimicrobial agents tested for publication III were erythromycin, 
levofloxacin, clindamycin, ceftriaxone, tetracycline, penicillin and moxifloxacin, 
and for publication IV they were erythromycin, levofloxacin, clindamycin, 
ceftriaxone, tetracycline and penicillin (280). Breakpoints were defined according to 
the guidelines of CLSI. 
4.5 Detection of serum antibodies and urinary 
antigens  
Serum antibodies to Mycoplasma pneumoniae, Chlamydia pneumoniae, Francisella 
tularensis and common respiratory viruses (adenovirus, parainfluenza virus, 
influenza A and B virus, enterovirus, respiratory synctial virus and Puumala virus) 
were analysed in the Central Hospital of Kainuu by enzyme immunoassay (EIA) and 
complement fixation methods from acute-phase sera of recruits. Legionella 
pneumophila antigens from urine were detected by the BinaxNOW® Legionella 
Urinary Antigen test (Binax Inc., Scarborough, ME, USA). 
4.6 Serotyping 
Pneumococcal isolates were serotyped by counterimmunoelectrophoresis or by latex 
agglutination (the neutral serogroups/types 7 and 14). The capsular swelling 
(Quellung) test was used for confirmation when needed. All Omni, pool, group/type 
and factor antisera were acquired from Statens Seruminstitut, Copenhagen, Denmark. 
4.7 Isolation of DNA and primers 
Chromosomal DNA extraction of MRSA isolates was performed by using the 
guanidium thiocyanate-EDTA-sarkosyl-reagent (GES reagent) or the rapid lysis 
buffer method (HainLifescience GmbH, Nehren, Germany) (281) (publications I and 
II). The genomic DNA of pneumococcal isolates was isolated with the DNeasy 
tissue kit (Qiagen GmbH, Hilden, Germany) or lysis method (239) (publications III 
and IV).  
 
The primers used in the publications are presented in Tables 4A and 4B. 
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Table 4A. Primers used in MRSA studies (publications I and II). 
Target Method Reference 
Protein A (spa) spa typing (3) 
Carbamate kinase (arcC) MLST (68, 96) 
Shikimate dehydrogenase (aroE) MLST (96) 
Glycerol kinase (glpF) MLST (96) 
Guanylate kinase (gmk) MLST (96) 
Phosphate acetyltransferase (pta) MLST (96) 
Triosephosphate isomerase (tpi) MLST (96) 
Acetyl coenzyme A acetyltransferase (yqiL) MLST (96) 
mec complex locus A  SCCmec typing (267) 
mec complex locus B  SCCmec typing (267) 
mec complex locus C  SCCmec typing (267) 
mec complex locus D  SCCmec typing (267) 
mec complex locus E SCCmec typing (267) 
mec complex locus F  SCCmec typing (267) 
mec complex locus G  SCCmec typing (267) 
mecA  MRSA identification, 
SCCmec typing 
(157, 193, 246, 267) 
 
ccrA1-ccrB SCCmec typing (164, 193) 
ccrA2-ccrB SCCmec typing (164, 193) 
ccrA3-ccrB SCCmec typing (164, 193) 
ccrA4-ccrB4 SCCmec typing (193) 
ccrC SCCmec typing (193) 
mecA-mecI (mec class A) SCCmec typing (193, 266) 
mecA-IS1272 (mec class B)   SCCmec typing (183, 193, 266) 
mecA-IS431 (mec class C) SCCmec typing (183, 193) 
mecR1 (PB domain) SCCmec typing (183, 266) 
mecR1 (MS domain) SCCmec typing (183, 266) 
SCCmec subtype IVa SCCmec typing (266) 
SCCmec subtype IVb SCCmec typing (266) 
PVL genes lukS-PV and lukF-PV PVL-PCR (214) 
Thermostable nuclease (nuc) MRSA identification (36) 
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Table 4B. Primers used in pneumococcal studies (publications III and IV). 
Target Method Reference 
Shikimate dehydrogenase (aroE) MLST (97) 
Glucose-6-phosphate 
dehydrogenase (gdh) 
MLST (99) 
Glucose kinase (gki) MLST (99) 
Transketolase (recP) MLST (97) 
Signal peptidase I (spi) MLST (282) 
Xanthine 
phosphoribosyltransferase (xpt) 
MLST (97) 
D-alanine-D-alanine ligase (ddl) MLST (30), B. Pichon, personal 
communication 
rlrA Pilus islet 1-PCR (2) 
rrgC Pilus islet 1-PCR (336) 
pitA-sipA Pilus islet 2-PCR (13) 
4.8 SCCmec typing by PCR 
For publication I, SCCmec typing of MRSA isolates was initially performed by 
multiplex PCR, as previously described (267). Non-typeable strains were further 
analysed for ccr (ccrAB and ccrC) and the mec gene complex by PCR, as described 
by Okuma and co-workers (266). For publication II, the ccr types (ccrAB1 to 
ccrAB4, or ccrC) and mec class (A, B, or C) within SCCmec were detected by 
multiplex PCR (M-PCR 1 and M-PCR 2), as previously described (193). 
4.9 Virulence gene detection by PCR  
4.9.1 PVL 
The presence  of PVL genes, lukS-PV and lukF-PV, of S. aureus isolates was 
detected by PCR (214). PVL encoding genes were amplified either alone or with nuc 
and mecA genes as a multiplex PCR (36, 246). Three strains were used as controls: 
CCUG 46923 (nuc+, pvl+), FIN-11 (ST80) (nuc+, pvl+, mecA+) and FIN-3 (ST5) 
(nuc+, mecA+). 
4.9.2 Pilus islet 1- and 2- PCR 
The presence of pneumococcal PI-1 genes (rlrA and rrgC) and PI-2 genes (pitA-sipA) 
was detected by PCR. The following strains were used as controls: IH152966-1 
[from NIDR, penR, serotype 19F, ST236, rlrA+, rrgC+, (pitA-sipA)+] and 
IHU60124 [AOM strain, serotype 6B, ST1752, rlrA-, rrgC-, (pitA-sipA)-]. 
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 4.10 Pulsed-field gel electrophoresis (PFGE) 
Pulsed-field gel electrophoresis (PFGE) was performed according to the harmonised 
protocol developed by consensus in ten European laboratories in 2003 (247). The 
strain NCTC 8325 was used as a reference standard. PFGE patterns were analysed 
with BioNumerics software (version 4.6 and 5.1, Applied Maths, Kortrijk, Belgium). 
The Dice coefficient was used to analyse the similarity of the banding patterns, and 
cluster analysis was performed by the unweighted pair group method using 
arithmetic averages (UPGMA). In general, the criterion of a difference of & 6 bands 
or a similarity cut-off of 80% was used to determine a PFGE type (345, 353). If a 
seven or more band difference occurred, the PFGE types were interpreted as 
different. In publication I, PFGE types having a 1–6 band difference in their PFGE 
band profile were considered to belong to the same PFGE cluster and were assigned 
the same FIN number, including strains with a 1–2 band difference. Strains with a 
3–6 band difference were named by letters after the FIN number. In publication II, 
PFGE types having a 1–6 band difference in their PFGE band profile were 
considered to belong to the same PFGE type, but were interpreted as different if a 
seven or more band difference occurred. PFGE subtypes were not defined. PFGE 
profiles differing by more than six bands, compared to any other profile in the local 
PFGE database, were interpreted as sporadic types. The interpretation criterion for a 
‘PFGE cluster’ in publication I corresponds with the criterion for a ‘PFGE type’ in 
publication II. 
4.11 Sequencing methods 
4.11.1 spa typing 
The polymorphic region of protein A gene (spa) was amplified by PCR and 
sequenced as described earlier (3, 343). Ridom StaphType software (Ridom GmbH, 
Würzburg, Germany) was used to analyse the sequences (140). Clustering of related 
spa types into clonal complexes (spa CC) was carried out by using the repeat pattern 
(BURP) algorithm of the Ridom StaphType software package (232). spa types were 
clustered if the calculated cost between members of a group was less than or equal 
to six (publication I) or four (publication II). spa types shorter than five repeats were 
excluded (publication II). A bioneighbour-joining tree of spa types was built by 
using the program Splits Tree4 (version 4.10). Cost values from the Ridom 
StaphType program were used to analyse the distances between spa types. 
4.11.2 Multilocus sequence typing (MLST) 
Multilocus sequence typing (MLST) was performed for MRSA and pneumococcal 
isolates as described previously (30, 96, 97, 99, 331). Seven housekeeping genes of 
MRSA isolates [carbamate kinase (arcC), shikimate dehydrogenase (aroE), glycerol 
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kinase (glpF), guanylate kinase (gmk), phosphate acetyltransferase (pta), 
triosephosphate isomerase (tpi) and acetyl coenzyme A acetyltransferase (yqiL)] and 
pneumococcal isolates [shikimate dehydrogenase (aroE), glucose-6-phosphate 
dehydrogenase (gdh), glucose kinase (gki), transketolase (recP), signal peptidase I 
(spi), xanthine phosphoribosyltransferase (xpt) and D-alanine-D-alanine ligase (ddl)] 
were amplified by PCR. The PCR products were purified using the QiaQuick PCR 
purification kit (Qiagen), the GeneClean Turbo kit (Q-Bio-Gene; MB Biomedicals, 
OH), or the Edge Bio QuickStepTM 2 PCR Purification kit (Edge Bio Systems, 
Gaithersburg, USA). The sequences were determined with an ABI Prism 310 
Genetic Analyzer by using BigDye fluorescent terminator chemistry (Applied 
Biosystems, UK) (publication I) or by using full service sequencing offered by the 
Molecular Medicine Sequencing Laboratory (Biomedicum, Helsinki) (publications 
II–IV). The forward and reverse sequencing primers for each gene were the same as 
those for initial PCR. To analyse and trim the sequences, the Vector NTI Advance 
10 software suite (Invitrogen Corporation, Carlsbad, CA) was used. The trimmed 
sequences were compared against the MLST database and the sequence types (STs) 
were assigned. The clonal complex (CC) for each ST was determined against the 
entire Staphylococcus aureus or Streptococcus pneumoniae database by eBURST 
V3 analysis using default stringent parameters. New allele sequence traces and STs 
were submitted to the MLST database.      
4.12 Cost and time analysis 
In publication II, the mean hands-on time and total time used for processing one set 
of isolates for PFGE (n = 12) and spa typing (n = 24) was estimated by stopwatch 
analysis. Each step of the process was timed at least three times by three different 
persons. The hands-on time included the time used for analysing the results. The 
material costs of both methods were calculated based on material usage per isolate. 
The Molecular Medicine Sequencing Laboratory (Biomedicum, Helsinki) provided 
the sequencing service for spa typing. 
4.13 Comparisons of typing methods and statistical 
analysis 
The discriminatory power of typing methods (discriminatory index, DI) and 
confidence intervals for DIs was calculated by using Ridom StaphType software 
(publications I and II) (131, 162). DI indicates the ability of two unrelated strains to 
fall into different typing groups and it depends on the total number of strains in the 
strain collection, the total number of strain types tested by the test method and the 
relative frequencies of these types (162). In publication I, DI calculation of SCCmec 
typing only included the SCCmec types, not the subtypes. 
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To assess the quantitative correspondence between typing methods, three different 
coefficients were used: Rand, Adjusted Rand (AR) and Wallace (W) (161, 297, 371). 
Ridom StaphType was used to analyse the Rand coefficient. AR and W coefficients 
were calculated via the Internet (www.comparingpartitions.info). The Rand and AR 
coefficients explore the concordance between typing methods, while the W 
coefficient value demonstrates the probability that two strains categorised as the 
same type by one method are also categorised as the same by another method. A 
high value for the W coefficient indicates that the result obtained by a given method 
could have been predicted from the result of the other method. 
 
In publication III, statistical data were analysed by Intercooled Stata 9.1 for 
Windows (StataCorp, College Station Texas, the USA). The risk ratios (RR) were 
calculated using univariate analysis and 95% confidence intervals (CI) for exposures 
of interest. The chi-squared test was used to compare categorical data. In publication 
IV, statistical analysis was performed with the free GraphPad software 
(http://www.graphpad.com). For categorical data, proportions were compared using 
Fisher’s exact test. In publications III and IV, P values <0.05 were considered 
statistically significant.  
4.14 Ethical considerations 
THL conducts infectious disease surveillance and research by legislation and has the 
rights to use data from the NIDR. No ethics committee approval was therefore 
required for publications I and II. For publication III, written informed consent was 
obtained from the all recruits involved in a point-prevalence survey. The 
experiments described in publication IV were carried out by using previously 
isolated strains of pneumococci. Written informed consent was obtained from the 
parents of all children before enrolment and the study protocol was approved by the 
ethics committees of THL (formerly Kansanterveyslaitos, KTL) and the University 
of Helsinki.  
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5 RESULTS 
5.1 Molecular characteristics of MRSA strains (I, II)  
5.1.1 Molecular characteristics of epidemic MRSA strains in Finland (I, II) 
The molecular characteristics of epidemic MRSA strains in Finland were 
investigated in detail by using several typing methods in publication I. During a 
thirteen-year period (from 1991 to 2004), 44 Finnish epidemic MRSA (EMRSA) 
strains were detected by PFGE. When these strains were reanalysed using PFGE 
with the looser PFGE interpretation criteria, these 44 EMRSA strains could be 
grouped into 26 PFGE clusters. Amongst the 44 EMRSA strains, 20 MLST STs 
with 12 CC, and 27 spa types with four spa CC and 7 singletons (spa types), were 
detected (Table 5 and Figure 10). In addition, most of the EMRSA strains possessed 
SCCmec type IV (43%), were multiresistant (52%) and PVL negative (95.5%). 
 
Table 5. Characteristics of EMRSA isolates from 1991–2004. 
MLST 
CC 
MLST 
ST 
spa CC spa PFGE 
cluster 
SCC
mec 
Resistance 
to multiple 
antibioticsa 
PVL  Year of 
isolation   
1 1 singleton t127 FIN-19 IV no -/+ c 2001 
5 5 002 t088 FIN-26 V no - 2004 
5 5 002 t002 FIN-3 II yes - 1992 
5 5 002 t002 FIN-3 II yes - 1999 
5 5 002 t001 FIN-8 IVA yes - 1994 
5 125 002 t067 FIN-16 IA yes - 2001 
8 8 051/008 t008 FIN-15 IV no - 2000 
8 8 051/008 t008 FIN-18 IV yes - 2000 
8 8 051/008 t008 FIN-25 IV no + 2004 
8 8 051/008 t596  FIN-7 IV no - 1997 
8 8 051/008 t008 FIN-7  IV no - 1993 
8 239 234/037 t037 FIN-13 III yes - 1998 
8 239 234/037 t030 FIN-2 III yes - 1994 
8 239 234/037 t037 FIN-2 III yes - 2000 
8 239 234/037 t037 FIN-2 III yes - 1998 
8 239 234/037 t234 FIN-2 IIIA yes - 1992 
8 239 234/037 t573  FIN-2 IIIA yes - 1993 
8 239 234/037 t030 FIN-9 IIIA yes - 1994 
8 241 234/037 t037 FIN-2 IIIB yes - 1998 
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8 247 051/008 t051 FIN-1 IVA yes - 1992 
8 247 051/008 t051 FIN-1 IVA yes - 1993 
8 247 051/008 t051 FIN-1 IVA yes - 1993 
8 247 051/008 t051 FIN-1  IVA yes - 1991 
8 247 051/008 t051 FIN-1 IA yes - 1992 
8 572 051/008 t562 FIN-1 IA yes - 1994 
9 27 singleton t100 FIN-22 V no - 2003 
12 12 singleton t561  FIN-14 IV no - 1998 
22 22 singleton t022 FIN-12 IV no - 1997 
30 30 234/037 t018 FIN-5  IV no -/+ c 1993 
30 36 234/037 t018 FIN-5  II yes - 1995 
45 45 065 t015 FIN-10 IV no - 1996 
45 45 065 t330 FIN-10 IV no - 1997 
45 45 065 t004 FIN-10  IV no - 1998 
45 45 065 t563 FIN-10  IV no - 1996 
45 45 065 t560 FIN-10  V nob - 2000 
45 46 065 t065 FIN-17  V no - 2000 
59 375 singleton t172 FIN-4 IV no - 1997 
59 375 singleton t172 FIN-4  IV no - 1993 
59 375 singleton t172 FIN-4  IV no - 1994 
72 72 singleton t148 FIN-20 IVA no - 2001 
80 80 singleton t044 FIN-11 IV nob + 1997 
228 111 002 t041 FIN-24 IV yes - 2004 
228 228 002 t041 FIN-21 I yes - 2002 
228 228 002 t001 FIN-23 IV yes - 2004 
a Multiresistant: resistant to % 3 antibiotics; Non-multiresistant: resistant to 1–2 antibiotics 
b Some isolates can also be multiresistant 
c Both PVL-positive and -negative isolates have been identified among the groups FIN-19 and 
FIN-5 
 
 
 
 
 
 
 
 
 
 Table 5. Continues. 
MLST 
CC 
MLST 
ST 
spa CC spa PFGE 
cluster 
SCC
mec 
Resistance 
to multiple 
antibioticsa 
PVL  Year of 
isolation   
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Figure 10. A bioneighbour-joining tree of 27 spa types of Finnish EMRSA isolates 
(N = 44). spa CCs are shown by red circles. S indicates a singleton spa type. MLST CCs 
and PFGE groups are mentioned after the spa CC or S. In two spa CCs, an additional 
MLST CC is found, besides the most common MLST CC. These MLST CCs are bolded 
and underlined after the spa type.    
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Nine spa types were found among 220 FIN-4 MRSA isolates between the years 1997 and 
2006 (Table 6). One of the isolates was non-typeable. The majority (87%, 191/220) of 
the isolates were of spa type t172. The spa types belonged to one spa cluster, spa CC 
172, and one of the isolates was a singleton. All of the three different STs belonged to 
one clonal complex (CC), CC59. Among eight spa types other than t172, seven 
possessed SCCmec type IV and one isolate was non-typeable. The non-typeable spa type 
also had a non-typeable SCCmec type. 
 
Among the 196 FIN-16 isolates, 12 spa types were found between the years 1997 and 
2006 (Table 6). All isolates belonged to one spa cluster, spa CC 002. spa type t067 (88%) 
was the most prevalent. All of the three different STs belonged to CC5. Among 11 spa 
types other than t067, eight possessed SCCmec type IV and the remaining three carried 
SCCmec type I, V, and a non-typeable SCCmec type. The both non-typeable spa types 
had also non-typeable SCCmec type. 
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Table 6. spa typing, MLST, and SCCmec results of MRSA FIN-4 and FIN-16 
isolates in Finland between 1997 and 2006.  
 
PFGE type spa typea 
(No. of 
isolates) 
spa CCb MLST STc MLST CCc SCCmeca,c 
FIN-4 NT (1) - 375 59 NT 
 t172 (191) 172 375d 59d IVd 
 t216 (1) 172 87 59 IV 
 t458 (1) excluded 375 59 IV 
 t529 (3) excluded 375 59 IV 
 t976 (1) 172 59 59 NT 
 t2380 (4) 172 375 59 IV 
 t3424 (2) excluded 375 59 IV 
 t3627 (15) 172 375 59 IV 
  t3718 (1) singleton 375 59 IV 
FIN-16 NT (2) - 5, 125 5 NT 
 t002 (8) 002 5 5 IV 
 t067 (172) 002 125 5 IV 
 t214 (3) 002 5 5 IV 
 t242 (1) 002 5 5 V 
 t442 (3) 002 146 5 IV 
 t535 (1) excluded 5 5 NT 
 t548 (1) 002 146 5 IV 
 t777 (1) excluded 125 5 IV 
 t952 (1) 002 5 5 I 
 t1094 (1) 002 5 5 IV 
 t1991 (1) excluded 125 5 IV 
  t3109 (1) 002 125 5 IV 
a NT, non-typeable 
b spa types were clustered if the calculated cost (using Ridom StaphType software) between members of  
a group was & 4; spa types shorter than five repeats were excluded. 
c Eight FIN-4 and 11 FIN-16 representative MRSA strains were selected for MLST and SCCmec typing, 
based on different spa typing results compared to the most common spa type found among the PFGE 
types. In addition, five FIN-16 strains with spa type t067 were selected for MLST. 
d MLST and SCCmec typing results are taken from the result of the representative FIN-4 EMRSA strain 
(index case).  
5.1.2 Molecular characteristics of MRSA blood isolates in Finland (II) 
The molecular characteristics of 124 Finnish MRSA blood isolates were studied in detail 
during 1997–2006 in publication II. Among 124 MRSA blood isolates, 19 different 
previously identified EMRSA strain types were detected by using PFGE (Table 7). In 
addition, six sporadic PFGE types were identified. spa typing was able to identify 38 
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different spa types, which divided into eight spa CC, including one without a founder, 
and 10 singleton spa types (12 isolates). The most prevalent PFGE types were FIN-16 
(34%), FIN-21 (15%) and FIN-4 (10%). Concordant with the PFGE types, the most 
prevalent spa types were t067 (32%), t041 (13%) and t172 (10%). 
 
Results 
  
 
 
  
 
Table 7. Characteristics of MRSA blood isolates in Finland between 1997 and 2006. 
PFGE type spa type  
(No. of isolates) 
spa CC No. of isolates (%) (N=124) Isolation year/years 
FIN-1 t562 singleton 1 (1%) 2000 
FIN-2  t037 012 4 (3%) 1998–1999, 2004 
FIN-3 t002 002 2 (2%) 2005, 2006 
t172 (12) no founder  13 (10%) 1999, 2001–2004, 2006 FIN-4 
t976 (1) no founder   2005 
t012 012 3 (2%) 2006 
t018 012  1997 
FIN-5  
t2163 singleton   2003 
t008 (3) 008 8 (6%) 2001, 2005, 2006 
t024 008  2005 
t068 (2) 008  2003, 2004 
t121 008  2006 
FIN-7 
t596 008   2006 
FIN-9 t030 012 1 (1%) 2005 
t015 (3) 015 8 (6%) 2005, 2006 
t550 singleton  2005 
t596 008  2002 
t630 015  2006 
t1644 excluded  2004 
FIN-10 
t3020 excluded   2004 
t044 (2) 376 3 (2%) 1999, 2005 FIN-11 
t376 376   2006 
FIN-12 t032 singleton 2 (2%) 2000, 2006 
FIN-13 t037 012 2 (2%) 1998 
FIN-14 t160 singleton 1 (1%) 1999 
t008 (2) 008 3 (2%) 2001, 2004 FIN-15 
t689 singleton   2004 
t067 (39) 067 42 (34%) 2002–2006 
t442 067  2006 
t1084 067  2005 
FIN-16 
t3148 067   2005 
t127 (2) singleton 3 (2%) 2002, 2004 FIN-19 
t267 376   2006 
FIN-20 t148 singleton 1 (1%) 2005 
t041 (14) 2521/041 18 (15%) 2004–2006 
t1628 (2) 2521/041  2006 
t2521 2521/041  2004 
FIN-21 
t3181 2521/041   2004 
FIN-24 t041 2521/041 1 (1%) 2005 
FIN-25 t008 008 1 (1%) 2006 
t037 (2) 012 7 (6%) 2002, 2004 
t041 2521/041  2004 
t067 067  2002 
t355 singleton  2006 
t583 015  2002 
sporadic 
t2099 singleton   2006 
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5.1.3 Clonality of MRSA (I, II) 
 
Finnish EMRSA isolates were compared with international MRSA clones based on 
the literature and the MLST database. At the time of analysis the 44 Finnish 
EMRSA strains were divided into 12 known MLST CCs by eBURSTv3. However, 
the same data can now be divided into 10 known clonal complexes (Figure 11). 
Various international MRSA clones have been recognised in Finland and are 
presented in Table 8. 
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5.2 Molecular typing of MRSA (I, II)  
5.2.1 Typeability, discriminatory power, concordance and Wallace 
coefficient of typing methods (I, II) 
A combined analysis of typeability, discriminatory power, concordance and Wallace of 
MRSA typing methods was performed based on data from publications I and II. The overall 
typeability of MRSA typing methods was high, >89% (Table 9). The discriminatory power 
varied between genotyping methods (Table 10). In general, PFGE, spa typing and MLST had 
a high DI, while SCCmec typing had the weakest DI. Minor variations in DIs of spa typing 
and PFGE methods were detected between publications I and II.  
 
Table 9. Typeability of MRSA genotyping methods. 
Method Publication No. of isolates No. of non-
typeable isolates
 Typeability 
PFGE  I 44 0 100% 
PFGE II 589 0 100% 
spa typing I 44 0 100% 
spa typing II 589 3 99.5% 
MLST  I 44 0 100% 
MLST II 24 0 100% 
SCCmec  I 44 0 100% 
SCCmec II 19 2 89.5% 
 
Table 10. Discriminatory power of MRSA genotyping methods. 
Method Publication  No. of isolates No. of 
different 
types/groups 
DI  95% CI  
PFGE I 44 44 1 [1.0-1.0] 
PFGE clustera I 44 26 0.952 [0.922-0.983] 
PFGE typea II 124 26 0.847 [0.798-0.895] 
MLST I 44 20 0.936 [0.906-0.965] 
MLST CC I 44 12 0.785 [0.679-0.892] 
spa I 44 27 0.968 [0.948-0.988] 
spa  II 124 38 0.866 [0.819-0.914] 
spa CC I 44 11 0.846 [0.798-0.893] 
spa CC II 124 17 0.811 [0.761-0.861] 
SCCmec I 44 5 0.637 [0.504-0.771] 
 a The interpretation criterion of  ‘PFGE cluster’ in publication I corresponds to the criterion of 
‘PFGE type’ in publication II 
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Generally, adjusted Rand showed much lower concordance values between typing 
methods than Ridom, which uses a coefficient that is formally equivalent to the Rand 
coefficient. According to AR, concordance was highest between MLST and PFGE 
clusters (AR = 0.641) in publication I (Table 11). The next highest was between spa 
CC and MLST CC (AR = 0.584), and spa CC and MLST (AR = 0.548). SCCmec 
typing showed the lowest concordance with all other typing methods (AR = 0.017–
0.141). In publication II, the concordances between typing methods were higher than 
in publication I, as calculated by AR (Table 11). Concordance among MRSA blood 
isolates was highest between spa CC and the PFGE type (AR = 0.845).  
 
Table 11. Concordances between MRSA typing methods as calculated by adjusted 
Rand (AR) and Ridom software. 
Typing methodsa Concordances 
of 44 EMRSA  
  Concordances 
of 124 blood 
MRSA    
  AR Ridom AR Ridom 
MLST-PFGE cluster 0.641 0.961 - - 
spa CC-MLST CC 0.584 0.874 - - 
spa CC-MLST 0.548 0.910 - - 
spa-MLST 0.507 0.955 - - 
spa-PFGE cluster/typeb 0.432 0.958 0.812 0.954 
spa CC-PFGE cluster/typeb 0.430 0.893 0.845 0.963 
MLST CC-MLST 0.403 0.850 - - 
MLST CC-PFGE cluster 0.309 0.833 - - 
spa CC-spa 0.304 0.877 0.787 0.949 
spa-MLST CC 0.205 0.815 - - 
SCCmec-spa CC 0.141 0.652 - - 
SCCmec-MLST 0.138 0.672 - - 
SCCmec-PFGE cluster 0.094 0.659 - - 
SCCmec-spa  0.075 0.656 - - 
SCCmec-MLST CC 0.017 0.586 - - 
a  spa types were clustered if the calculated cost (using Ridom StaphType software) between 
members of a group was & 6 (publication I) or & 4 (publication II) and spa types shorter than five 
repeats were excluded. 
b The interpretation criterion of  ‘PFGE cluster’ in publication I corresponds with the 
criterion of ‘PFGE type’ in publication II 
 
In publication I, PFGE clusters completely predicted MLST CC (W = 1.00) and spa 
CC (W = 1.00) calculated by the Wallace coefficient. In addition to spa CC 
(W = 1.00), spa types highly predictied MLST CC (W = 0.9667), MLST ST 
(W = 0.8) and SCCmec (W = 0.8). MLST ST fully predict spa CC (W = 1.00) and 
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MLST CC (W = 1.00). SCCmec poorly predicted all typing methods. Overall, PFGE 
clusters and spa types were poorly predicted by other typing methods in publication I. 
In publication II, the spa type highly predicted the PFGE result (W = 0.9009) (Table 
12). In addition, PFGE had high probability of predicting spa CC (W = 0.9870). 
 
Table 12. Wallace coefficients for typing methods among 124 MRSA blood isolates.   
Typing Method spa spa CC PFGE  
spa   1.000 0.9009 
spa CC 0.6975  0.7810 
PFGE  0.7853 0.9870   
5.2.2 Short- and long-term correspondence between PFGE and spa 
typing methods (II) 
The short- and long-term correspondence between PFGE and spa typing was studied 
in detail among FIN-4, FIN-16 and MRSA blood isolates in publication II. The short-
term correspondence was high among FIN-4 and FIN-16 isolates, the majority of 
which in 2006 had only one spa type: t172 (81%) and t067 (93%), respectively. In 
addition, most of the FIN-4 and FIN-16 isolates belonged to one spa CC, namely spa 
CC 172 (94%) and spa CC 002 (98%), respectively. However, the correspondence 
between PFGE and spa typing among sporadic isolates (determined by PFGE) from 
2006 was rather low. PFGE and spa typing also corresponded well in the long term 
(between 1997 and 2006) among FIN-4 and FIN-16 isolates. Among FIN-4 isolates, 
92% had spa type t172 and 99% belonged to spa CC 172.  Of the FIN-16 isolates, 
80% had spa type t067 and 96% belonged to spa CC 002. The correspondence 
between PFGE and spa typing of the MRSA blood isolates varied between 1997 and 
2006 (Table 9). FIN-4, -5, -7, -10, -11, -15, -16, -19 and -21 showed variation in spa 
types. However, within five of these PFGE types (FIN-4, -7, -11, -16 and -21), the 
spa types belonged to same spa CC. The correspondence between PFGE and spa 
typing was high among the two most prevalent MRSA blood isolates, FIN-16 and 
FIN-21. Of the FIN-16 isolates, 93% had spa type t067, and of the FIN-21 isolates, 
86% had spa type t041. FIN-10 was the most variable PFGE type; of the eight FIN-
10 isolates, six different spa types were detected.  
5.2.3 Cost and time analysis (II) 
Cost and time consumption were compared between PFGE and spa typing methods. 
The total time required to type 12 isolates using PFGE was 40 h, and the time for 24 
isolates by spa typing was 9 h 15 min. For both methods, the hands-on time needed 
was 6 h 30 min. The material cost for PFGE was approximately '5/isolate and for 
spa typing approximately '9/isolate. 
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5.2.4 Nomenclature of MRSA in Finland (I, II) 
The nomenclature changes for MRSA strains in Finland were based on changes in 
typing methods described in publications I and II. In March 2005, new MRSA 
nomenclature was gradually introduced (Figure 12). Based on the new PFGE 
interpretation criteria of EMRSA strains, the 26 PFGE clusters were assigned FIN 
names with a numeric code (e.g. FIN-16). The numeric code was given in 
chronological order starting from the strain isolated first. Within each cluster of 
PFGE types, those with a 3–6 band difference were indicated by letters after the FIN 
number (e.g. FIN-1b). The new complete MRSA name consisted of the FIN name 
(based on the PFGE type) combined with the MLST sequence type and SCCmec type 
[e.g. FIN-4 (375;IV)]. At the beginning of 2009, the nomenclature of MRSA strains 
changed again due to the replacement of PFGE with spa typing as the first-line 
typing method. The new MRSA strain name is based on the spa type (e.g. t172).  
 
 
 
Figure 12. Changes in the nomenclature of EMRSA strains in Finland since the early 
1990s in relation to this thesis research.  
5.2.5 The current scheme for molecular typing of MRSA in Finland (II) 
In Finland, clinical laboratories send MRSA isolates corresponding to the NIDR-
reported MRSA cases to the Staphylococcal Reference Laboratory at THL for 
genotyping. The current typing scheme for MRSA was introduced at the beginning 
of 2009 and includes two typing categories: primary typing and additional typing. 
The MRSA typing scheme is presented in Figure 13. Primary typing is performed for 
all MRSA strains. Additional typing with different typing methods is carried out in 
specific instances. PFGE is performed if a new spa type is encountered, in Finland or 
according to SpaServer, in situations where the spa type is known to be associated 
with multiple PFGE types, or on occasions when the isolate is not typeable with spa 
typing. In addition, if a new spa type is encountered from at least five persons, 
additional typing such as MLST, SCCmec and PVL-PCR is performed. Moreover, 
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the presence of the PVL-encoding gene is defined from strains isolated from deep 
wounds, abscesses or puncture specimens. 
 
 
Figure 13. MRSA typing scheme in Finland from the beginning of 2009.  
5.3 Molecular characteristics of Streptococcus 
pneumoniae strains and pneumococcal pneumonia 
outbreak investigation (III, IV) 
5.3.1 Molecular characteristics of S. pneumoniae in community-
acquired pneumonia and nasopharyngeal carriage (III) 
The molecular characteristics of S. pneumoniae isolates detected from the blood 
and/or nasopharynx of military recruits were examined in detail in publication III. Of 
the 43 military recruits sharing the same housing during their military service, two 
had confirmed pneumococcal pneumonia defined as positive blood culture for S. 
pneumoniae. Both of the isolates were of serotype 7F, ST2331, CC2331, susceptible 
to penicillin and other commonly used antimicrobial agents. Neither of the isolates 
carried pilus islet 1 (PI-1). 
 
Of the 43 military recruits, 18 (42%) carried S. pneumoniae in their nasopharynx. 
Nine (50%) of these isolates had the same serotype and genotype as the blood 
Results 
THL  –- Research 71/2012 69 
Molecular Methods for the 
Epidemiological Analysis of MRSA  
                   and S. pneumoniae  
  
  
  
    
  
  
 
 
isolates from the hospital recruits: 7F and ST2331. Other serotype-genotype 
combinations detected were: 9N-ST525 (n = 5, 28%), 23F-ST36 (n = 3; 17%) and 
16-ST30 (n=1, 6%). All the nasopharyngeal isolates were susceptible to penicillin 
and other commonly used antimicrobial agents, and did not carry PI-1 in their 
genome.  
5.3.2 Molecular characteristics of S. pneumoniae in acute otitis media 
and nasopharyngeal carriage (IV)  
The molecular features of pneumococcal isolates found from MEF and/or NPA 
samples were defined by using various typing methods in publication IV. Among the 
106 children with clinically diagnosed AOM, 56 (53%) children were found to be 
culture-positive for S. pneumoniae. These children were divided into three groups on 
the basis of the site of pneumococcal isolation: (1) MEF+/NPA+ (n = 19); (2) 
MEF+/NPA- (n = 3); and (3) MEF-/NPA+ (n = 34). All 75 pneumococcal isolates 
were susceptible to penicillin (MIC & 0.06 µg/mL), one was non-susceptible to 
erythromycin (MIC & 0.5 µg/mL) and two to tetracycline (MIC & 4 µg/mL). Among 
these 75 isolates, 14 different serotypes were detected. The most prevalent serotypes 
were 19F (27%) and 23F (25%).  
 
Of the 75 isolates, 15 (20%) were positive for PI-1 genes (rrgC and rlrA). PI-2 genes 
were not found in any of the isolates. PI-1 genes were detected among serotypes 6B 
(6/7 isolates), 6A (4/5 isolates), 9V (2/2) isolates, 23F (2/19 isolates), and 38 (1/1 
isolate). Among MEF+/NPA+, 20% (8/41) of the pneumococcal isolates from four 
children contained PI-1 genes, and among MEF-/NPA+ the corresponding proportion 
was 21% (7/34). None of the three children with MEF+/NPA- had pneumococcal 
isolates with PI-1 genes.  
 
Of the 75 isolates from 56 children, 52 isolates from 33 children were genotyped by 
MLST. To select the isolates for MLST, several criteria were used: 1) all isolates 
from children with MEF- and NPA-positive samples; 2) all PI-1-positive isolates; 3) 
one isolate for each serotype; 4) positive and negative PI-1 gene results of serotypes 
6A, 6B, and 23F. Many of the isolates shared several of these criteria. The 52 isolates 
divided into 30 different STs and into 18 known CCs (Table 13). In addition, three 
STs had no predicted founder and two were singletons. The most prevalent CCs were 
CC439 (11/52; 21%) and CC490 (6/52; 12%). Nine of the 30 STs were related to 
known international pneumococcal clones (Table 13). Among MEF+/NPA+ 
children, the serotype and sequence type were the same in both samples. 
 
PI-1 genes were found among six CCs: CC138, CC156, CC393, CC439, CC490 and 
CC522 (Figure 14). PI-1 genes were most prevalent in CC490 (6/6). PI-1 was 
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associated with genotype CC490 (p = 0.002) and with serotypes 6A (P < 0.005), 6B 
(P = 0.0002), and 9V (P < 0.05). PI-1 was not associated with the pneumococcal 
conjugate vaccine 7 (PCV7) or 10 (PCV10) serotypes compared to non-
PCV7/PCV10 serotypes (PCV7 and PCV10, 10/56 vs. 5/19; P = 0.51). In addition, 
PI-1 was not associated with the PCV13 serotypes (14/56 vs. 1/19; P = 0.10). 
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Table 13. Molecular characteristics of the 52 pneumococcal isolates from 33 children. 
CCa STb Related international 
(PMEN) clone 
PI-1 
genes 
Serotype carried 
by the child  
Site of 
isolation 
Age 
(mo)  
15 15 SLV of England14-ST9 - 19F MEF+/NPA+c 24 
43 43 none - 19F MEF+/NPA+ 41 
  526 none - 19F MEF+/NPA+ 19 
62 500 none - 11A MEF+/NPA- 41 
66 2216 none - 15A MEF-/NPA+ 10 
72 72 none - 24 MEF+/NPA+ 10 
100 100 none - 6A MEF-/NPA+ 13 
113 4126 SLV of Netherlands18C-
ST113 
- 18C MEF-/NPA+ 13 
124 124 Netherlands14-ST124 - 14 MEF+/NPA+ 72 
  124 Netherlands14-ST124 - 14 MEF+/NPA+ 28 
138 138 none + 6B MEF-/NPA+ 50 
  4594 none + 6B MEF-/NPA+ 9 
156 162 SLV of Spain 9V-ST156 + 9V MEF+/NPA+ 52 
180 180 Netherlands3-ST180 - 3 MEF-/NPA+ 23 
199 199 Netherlands15B-ST199 - 19F MEF+/NPA+ 11 
393 310 None + 38 MEF-/NPA+d 42 
439 33 SLV of Tennesssee23F-ST37 - 23F MEF+/NPA+ 9 
 36 none - 23F MEF+/NPA- 39 
 37 Tennesssee23F-ST37 - 23F MEF+/NPA+ 50 
 37 Tennesssee23F-ST37 - 23F MEF+/NPA+ 9 
 355 SLV of Tennesssee23F-ST37 - 23F MEF+/NPA+ 20 
  515 none + 23F MEF+/NPA+ 33 
460 460 none - 6A MEF-/NPA+ 21 
490 208 none + 6B MEF+/NPA+ 41 
 488 none + 6A MEF-/NPA+ 32 
 490 none + 6A MEF-/NPA+ 32 
 490 none + 6A MEF-/NPA+ 50 
  518 none + 6A MEF-/NPA+ 36 
522 522 none + 6B MEF+/NPA+ 13 
1523 1340 none - 19F MEF+/NPA+ 53 
NPF 482 none - 19A MEF+/NPA+ 12 
NPF 1752 none - 6B MEF+/NPA- 11 
S 1069 none - 19A MEF+/NPA+ 50 
a CC named after the ST with the highest number of single-locus variants in the MLST database 
(November 2009). S, singleton; NPF, no predicted founder. 
b New STs are underlined. 
c non-susceptible to erythromycin  
d non-susceptible to tetracycline  
PMEN, Pneumococcal Molecular Epidemiology Network; SLV, single-locus variant 
 
  
 
  
  
  
  
    
  
  
 
 
 
 
 
 
 
 
Figure 14. Clonal complex distribution of 47 study isolates and the prevalence of  
PI-1 among the CCs. Corresponding serotypes are presented in parentheses. In 
addition to known CCs, three isolates with no predicted founder and two singletons 
were detected.   
 
5.3.3 Pneumococcal pneumonia outbreak investigation (III) 
An outbreak investigation of pneumococcal pneumonia was conducted among 
military recruits participating in a one-week hard encampment. Five (12%) of the 43 
military recruits were hospitalised with pneumonia. Two (5%) of 43 recruits were 
diagnosed as confirmed pneumonia cases and three (7%) as non–bacteraemic 
pneumonia cases. Pneumococcal isolates were cultured from the blood of confirmed 
pneumonia cases.  Three of the five hospitalised recruits also had radiographically 
confirmed sinusitis (both confirmed pneumococcal pneumonia cases and one non-
bacteraemic pneumonia case). Eighteen (42%) of the 43 recruits carried S. 
pneumoniae in their nasopharynx. Staphylococcus aureus was found from six 
nasopharyngeal cultures of the 43 recruits and !-haemolytic streptococci (groups G 
and C) from two nasopharyngeal cultures. None of the hospitalised recruits carried S. 
pneumoniae or S. aureus at the time the nasopharyngeal swab was taken for the 
point-prevalence study. Three of the 43 recruits were nasopharyngeally co-colonised 
by S. aureus and S. pneumoniae. In addition, group G streptococci were detected in 
one these co-colonised recruits. A group C streptococcus was isolated in the 
nasopharynx of one of the non-bacteraemic pneumonia cases.  
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Acute-phase sera of four of the five hospitalised recruits tested negative for viral and 
M. pneumoniae antibodies, and urine samples were negative for L. pneumophila.  
 
All recruits were previously healthy young men with a median age of 20 years (range 
19 to 21) without any continuous medications or underlying chronic diseases.  
In order to study the preceding symptoms of the 43 recruits, they were divided into 
three different groups: hospitalised recruits (n = 5), pneumococcal carriers (n = 18) 
and non-pneumococcal carriers (n = 20). Symptoms that were asked about were fever, 
rhinitis, sore throat and cough. Fever (5/5, 100%) and cough (4/5, 80%) were the 
predominant preceding symptoms among the hospitalised recruits, and rhinitis was a 
common preceding symptom in all three groups (Table 14). Of the 43 recruits, 35 
(81%) had some respiratory symptoms and 8 (19%) did not have any respiratory 
symptoms. Three of the 18 pneumococcal carriers had no preceding symptoms. The 
onset of respiratory symptoms, the dates of encampment and hospital stays are 
represented in an epicurve (Figure 15).  
 
Table 14. The preceding respiratory symptoms of 43 military recruits. 
 
  
 
Data on smoking habits was obtained from 42 of the 43 recruits. Twenty-three (55%) 
of the 42 recruits were active smokers, and 12 (52%) of the 23 smoking recruits were 
pneumococcal carriers. Cigarette smoking was not seen to be a significant risk factor 
for overall pneumococcal carriage, nor for confirmed or non-bacteraemic pneumonia.  
 
All the hospitalised recruits were treated with antimicrobial agents. In addition, two 
of the non-hospitalised recruits were treated for their symptoms as out-patients with 
antimicrobial agents before the encampment and four during or after the encampment, 
but none due to pneumonia. The usage of antimicrobial agents during the previous 
month was not associated with pneumococcal carriage (RR, 0.4; 95% CI, 0.11–1.50; 
P = 0.11).  
 
All the recruits with confirmed and non-bacteraemic pneumonia fully recovered and 
no more pneumonia cases were detected.  
  
Respiratory 
symptoms 
Hospitalised 
recruits 
Pneumococcal 
carriers 
Non 
pneumococcal 
carriers 
Total 
Fever 5/5 (100%) 7/18 (39%) 5/20 (25 %) 17/43 (40 %) 
Rhinitis 3/5 (60 %) 13/18 (72 %) 13/20 (65 %) 29/43 (67 %) 
Sore throat 2/5 (40 %) 5/18 (28 %) 8/20 (40 %) 15/43 (35 %) 
Cough 4/5 (80 %) 8/18 (44 %) 4/20 (20 %) 16/43 (37 %) 
None 0/5 (0 %) 3/18 (17 %) 5/20 (25 %) 8/43 (19 %) 
 
THL  –- Research 71/2012 74 
Molecular Methods for the 
Epidemiological Analysis of MRSA  
                   and S. pneumoniae  
  
  
  
    
  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
  
 
  
  
  
  
  
  
  
 
 
   
 
 
  
  
  
  
 
                       Fi
gu
re
 1
5.
 E
pi
cu
rv
e 
of
 th
e 
on
se
t o
f r
es
pi
ra
to
ry
 s
ym
pt
om
 in
 3
0 
m
ili
ta
ry
 re
cr
ui
ts
 b
et
w
ee
n 
1.
5–
30
.6
.2
00
6.
 E
ac
h 
bo
x 
in
di
ca
te
s 
on
e 
ca
se
. 
Se
ro
ty
pe
s 
of
 p
ne
um
oc
oc
ca
l 
is
ol
at
es
 c
ul
tu
re
d 
fr
om
 t
he
 n
as
op
ha
ry
nx
 a
nd
 b
lo
od
 a
re
 m
ar
ke
d 
in
 t
he
 b
ox
. 
B
la
ck
 b
ox
, 
co
nf
irm
ed
 
pn
eu
m
oc
oc
ca
l 
pn
eu
m
on
ia
 c
as
es
; 
da
rk
 g
re
y 
st
rip
ed
 b
ox
, 
no
n-
ba
ct
er
ae
m
ic
 p
ne
um
on
ia
 c
as
es
; 
gr
ey
 b
ox
, 
pn
eu
m
oc
oc
ca
l 
ca
rr
ie
rs
 w
ith
 
re
sp
ira
to
ry
 s
ym
pt
om
s;
 w
hi
te
 b
ox
, n
on
-c
ar
rie
rs
 w
ith
 r
es
pi
ra
to
ry
 s
ym
pt
om
s. 
In
 a
dd
iti
on
 to
 c
as
es
 m
ar
ke
d 
in
 th
e 
ep
ic
ur
ve
, 8
/4
3 
re
cr
ui
ts
 
ha
d 
no
 re
sp
ira
to
ry
 s
ym
pt
om
s 
(3
 p
ne
um
oc
oc
ca
l c
ar
rie
rs
, 5
 n
on
-p
ne
um
oc
oc
ca
l c
ar
rie
rs
) a
nd
 5
/4
3 
re
cr
ui
ts
 h
ad
 re
sp
ira
to
ry
 s
ym
pt
om
s 
bu
t 
th
e 
on
se
t 
da
y 
w
as
 l
ac
ki
ng
 (
2 
pn
eu
m
oc
oc
ca
l 
ca
rr
ie
rs
, 3
 n
on
-p
ne
um
oc
oc
ca
l 
ca
rr
ie
rs
). 
Th
e 
bl
oo
d 
sa
m
pl
es
 o
f 
th
e 
ho
sp
ita
lis
ed
 r
ec
ru
its
 
w
er
e 
ta
ke
n 
on
 1
9.
6.
 a
nd
 t
he
 n
as
op
ha
ry
ng
ea
l 
sw
ab
 s
pe
ci
m
en
s 
fr
om
 a
ll 
th
e 
re
cr
ui
ts
 w
er
e 
ta
ke
n 
on
 2
9.
6.
20
06
 a
nd
 5
.7
.2
00
6.
Results 
No. of cases 
O
ns
et
 o
f r
es
pi
ra
to
ry
 s
ym
pt
om
s 
En
ca
m
pm
en
t 
    
H
os
pi
ta
l s
ta
y 
(N
=4
) 
 
   
   
  H
os
pi
ta
l s
ta
y 
(N
=1
)
 
THL  –- Research 71/2012 75 
Molecular Methods for the 
Epidemiological Analysis of MRSA  
                   and S. pneumoniae  
  
  
   
  
  
  
 
 
6 DISCUSSION 
6.1 Staphylococcus aureus  
6.1.1 Molecular characteristics and clonality of MRSA  
Most of the EMRSA strains, isolated during the years 1991–2004, belonged to 
MLST CC8, which can be divided into five STs, two spa CCs and eight PFGE 
clusters. MLST CC8 included several internationally distributed clones such as 
Iberian (ST247-I), Brazilian (ST239-IIIA), Hungarian (ST239-III) and USA300 
(ST8-IV) clones (356, 398). The PVL-positive USA300 clones have been associated 
with CA-MRSA infections in several European countries and in USA (84, 98, 139). 
MLST CC5 included two different STs: ST5 and ST125. These STs are related to 
New York/Japan (ST5-II) and paediatric clones (ST5-IVA), which are well-known 
HA-MRSA-associated pandemic clones (81, 398). Two major HA-MRSA clones, 
UK EMRSA-15 and -16, were also identified in Finland. These clones were first 
identified in the UK at the beginning of the 1990s and are now distributed 
worldwide (175). Thus, many international clones have been identified in Finland. 
In addition, according to the S. aureus MLST database, most of the Finnish MRSA 
strains belong to the major clonal complexes (238). However, some of the Finnish 
EMRSA strains were isolated from local outbreaks with sporadic PFGE profiles and 
rare MLST results. FIN-22 (ST27-V), which caused an outbreak in a long-term care 
facility in northern Finland in 2003, is one example (185).  
 
More than half of the Finnish EMRSA strains were multiresistant. In particular, 
SCCmec types II and III cause additional non-!-lactam antimicrobial resistance to 
multiple classes of antimicrobials, due to the additional drug resistance genes 
integrated into SCCmec, i.e. integrated plasmids and two transposons (81). 
Moreover, S. aureus can also harbour resistance genes on other sites of the genome, 
as well as on plasmids (216). In this study, the antimicrobial susceptibility profiles 
mainly corresponded with the assumed resistance characteristics of the SCCmec 
complex of the strain. However, disconcordance between the antibiogram and 
SCCmec type was noted within three PFGE clusters, which could result from 
additional resistance genes found elsewhere in the genome. Unfortunately, the 
antibiograms were not included in publication II due to technical reasons.  
 
Only two of the EMRSA strains, FIN-11 (ST80-IV) and FIN-25 (ST8-IV), were 
positive for PVL encoding genes. ST80 is a widely disseminated PVL-positive ST in 
European countries, and ST8 in the United States (USA300) (85, 381). Both of these 
strain types have been associated with CA-MRSA worldwide. The PVL-positive 
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FIN-11 (ST80-IV) strain has also been verified to have community acquisition in 
Finland (181, 182, 184, 311). In addition, the presence of PVL encoding genes 
varied in some of the strains, such as in FIN-19 (ST1-IV) and FIN-5 (ST30-IV). 
These strains are related to two PVL-positive CA-MRSA clones, USA400 (ST1-IV) 
and Southwest Pacific (USA1100) (ST30-IV), which are disseminated worldwide 
(81). In accordance with this study, PVL-positive and -negative strains have been 
identified among the USA400 strains (266). SCCmec types I, II, III and rarely IV are 
typically considered as markers for HA-MRSA (81). In contrast to HA-MRSA, the 
majority of CA-MRSA isolates tend not to be multiresistant, and SCCmec types IV, 
V and VII, as well as PVL, are typically present (53, 81). However, the distribution 
of these markers among CA-MRSA and HA-MRSA is not complete. The presence 
of PVL among CA-MRSA is more variable, and in Denmark, for example, the 
prevalence of PVL ranged from 17% to 100% (208). In addition, PVL has also been 
detected in the hospital environment (200). During recent years, the distinction 
between HA-MRSA and CA-MRSA has started to disappear. CA-MRSA strains 
such as USA300 can also cause infections in hospitals, and clones traditionally 
linked to hospitals, such as EMRSA-15, can cause infections in the community (81, 
200, 260). 
 
EMRSA strains FIN-4 and FIN-16 were investigated in more detail in publication II. 
The study revealed that FIN-4 isolates as well as FIN-16 isolates were genetically 
closely related analysed by spa typing. In addition, both FIN-types belonged to only 
one MLST CC, CC59 (FIN-4) and CC5 (FIN-16). Moreover, SCCmec IV was 
predominant among FIN-4 isolates, whereas variation in SCCmec types was noted 
among FIN-16 isolates. One small cluster was recognised among the FIN-4 isolates 
with spa type t3627 (closely related to t172) in 2006. The strains were isolated from 
the same healthcare centre during June and July, and were also found in 2002 and 
2003 from the same healthcare district. FIN-4 isolates comprised 10% of all MRSA 
isolates between 2004 and 2006 in Finland. In addition, FIN-4 isolates are known to 
have community acquisition and are found throughout Finland (181). According to 
the Ridom SpaServer, spa type t172 has been identified in several European 
countries, but to the best of our knowledge, it does not belong to the most prevalent 
type of strains in clinical settings outside the Nordic countries (326). Recently, 
MRSA isolates with spa type t172 were detected as the most commonly found 
MRSA in municipal wastewater in Sweden. These isolates probably originated from 
human carriage, because the genotypes of the isolates corresponded to those in 
clinical settings (42). Outbreaks caused by FIN-16 seem to be responsible for the 
increase in reported MRSA cases observed from 1997 to 2004 in Finland (184). In 
addition, between 2004 and 2006, FIN-16 comprised nearly one-third of all MRSA 
isolates in Finland (310). FIN-16 is related to the highly prevalent Spanish clone 
ST5-IV with spa type t067 (388). Several Spanish studies have reported that this 
clone is associated to HA-MRSA infections in Spain (10, 274, 388). spa type t067 
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has also been sporadically identified from Sweden and countries of Central Europe, 
such as France and Germany (130, 231, 241, 277). A German study reported one 
occasion where the Spanish clone was found from a patient who was repatriated 
from the Canary Islands (241). In addition, according to Ridom SpaServer, spa type 
t067 isolates have been identified in several European countries and in the US (326). 
According to recent MRSA data from Finland, t067 and t172 were the two most 
prevalent spa types in 2009 and 2010 (358, 360). spa types t067 and t172 
respectively comprised 28% and 14% of cultured and confirmed MRSA cases in 
2010. In 2010, spa type t172 was found from 16 hospital districts and spa type t067 
from 9 hospital districts, most commonly in the Pirkanmaa hospital district (360). 
 
In Finland, 124 genetically diverse EMRSA blood isolates were detected between 
1997 and 2006. The most common spa types were t067 and t041. FIN-16 (t067) and 
FIN-21 (t041), internationally distributed and multi-drug-resistant EMRSA strains, 
were related to the increase in reported MRSA cases detected from 1997 to 2004 
(184). According to a recent study of European invasive S. aureus covering the 
years 2006 and 2007, spa type t041 was also found to be frequent among invasive 
MRSA isolates (130). The study additionally demonstrated that spa type t041 was 
the most or the second most common invasive MRSA finding in Italy, Slovenia, 
Croatia, Austria, and Hungary. On the other hand, spa type t067 was the sixth most 
frequent finding among the study isolates and was the predominant finding in Spain 
(130). In 2010, fifteen MRSA isolates were cultured from blood in Finland. Six of 
these had spa type t067, and the rest represented eight different spa types (360). 
However, none of the spa types were t041 (unpublished data).  
 
6.2 Streptococcus pneumoniae 
6.2.1 Molecular characteristics of S. pneumoniae 
Pneumococcal serotype 7F was the most prevalent pneumococcal serotype detected 
among military recruits. According to Finnish surveillance data on invasive 
pneumococci, serotypes 7F, 9N, and 23F have been among the 10 most prevalent 
serotypes causing invasive diseases for several years. To date, three invasive isolates 
of ST2331 with 7F/7 have been  reported to the international MLST database (238). 
In addition, four isolates with ST2331 were found among adult patients with 
community-acquired pneumonia in Japan (163). Although serotype 7F has been 
associated with decreased risk of death due to IPD and is rarely found among 
healthy carriers, it has a high invasive disease potential (336, 383). PI-1 genes have 
been shown to be absent from serotype 7F, but the prevalence of PI-2 has been 
shown to be 89% among serotype 7F (2, 406). Unfortunately, PI-2 genes were not 
studied from the isolates of our material. 
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The pneumococcal serotypes isolated from children with clinically diagnosed AOM 
were the common ones known to be associated with AOM infections among 
children (101). The 10-valent pneumococcal conjugate vaccine (PCV10) would have 
covered 75% of the serotypes detected. This is of special interest, because in Finland 
the large-scale use of PCV10 began in September 2010, and consequences of the 
vaccination will be seen in the near future. Several studies have showed an 
increasing trend of S. pneumoniae infections caused by non-PCV7 serotypes after 
introducing the PCV7 (45, 150, 333). 
 
The MLST STs of the MEF and NPA isolates showed great heterogeneity. Nine of 
the 30 MLST STs were related to international clones [Pneumococcal Molecular 
Epidemiology Network (PMEN clones)] (283). Two of these, ST156/CC156 and 
ST199, have also been observed among isolates from MEF of children with AOM in 
previous studies (242, 397).  
 
In the early 1990s, the overall antimicrobial resistance of S. pneumoniae was very 
low in Finland (223). The study isolates from MEF and NPA were collected in 
1990–1992, and all the isolates were susceptible to penicillin and almost all to other 
commonly used antimicrobials. However, the antimicrobial resistance of S. 
pneumoniae has also increased in Finland, and between 2002 and 2006 the penicillin 
non-susceptibility of invasive pneumococcal isolates increased from 8% to 16% and 
erythromycin non-susceptibility from 16% to 28% (331). 
 
So far, the prevalence of pneumococcal PI-1 genes has mainly been studied among 
invasive isolates. According to previous studies, the prevalence of PI-1 among 
pneumococcal isolates cultured from invasive and community-acquired pneumonia 
diseases has been around 30% (2, 163, 243). The frequency of PI-1 among the MEF 
isolates has been shown to be the same 30% (242). In the US, the prevalence of PI-1 
among nasopharyngeal isolates was shown to decrease from 24% to 15% after the 
introduction of PCV7. However, in 2007 it increased to pre-PCV7 level (292). In 
2008, Bagnoli et al. described a second pilus type, referred as PI-2, in S. pneumoniae 
(13). The prevalence of PI-2 has been shown to be 16% for both invasive and 
nasopharyngeal isolates, and 7% for the MEF isolates (13, 242). In the US, the 
prevalence of PI-2 was shown to increase among invasive isolates from 3.6% in 
1999 to 21% in 2006, after introducing the PCV7 (in 2000) (406). This study 
demonstrated that only 20% of the MEF and/or NPA isolates were positive for PI-1 
and none for PI-2.  
 
Previous reports have demonstrated a positive correlation between PI-1 and 
antimicrobial resistance (2, 242, 243). Thus, the lower prevalence of PI-1 in our 
material, compared to other studies could be due to low antimicrobial resistance in 
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the period in which the isolates were collected. PI-1 has been found to be associated 
with the PCV7 vaccine serotypes 4, 6B, 9V, 14, and 19F, whereas PI-2 was mainly 
found from non-PCV7 serotypes (1, 7F 11A, 19A), except for the serotype 19F (2, 
18, 406). However, the presence of PI-1 was not associated with the PCV7 serotypes 
compared to the non-PCV7 serotypes in this study.  
 
Several investigations have demonstrated that the presence of PI-1 and PI-2 appears 
to be a clonal property rather than serotype-associated (2, 13, 18, 242, 243, 292, 
406). In contrast to these reports, in this study PI-1 associated more commonly with 
certain serotypes than genotypes. On the other hand, no STs or CCs that have been 
reported as PI-2 positive were found, which may explain the absence of PI-2. The 
lack of PI-2 could be also due to the small number of isolates. The low antimicrobial 
resistance of the isolates hardly explains the missing of PI-2, because Zähner at al. 
have reported that antimicrobial resistance is not a consistent property of PI-2-
positive isolates (406).  
 
PI-1 is not considered as a recently acquired feature of S. pneumoniae, but has 
existed among pneumococcal isolates prior to pneumococcal conjugate vaccine and 
the increase in antimicrobial resistance (292). This was also demonstrated in our 
study. Recently, Zähner et al. reported that PI-2 was also present among invasive 
pneumococcal isolates prior to pneumococcal conjugate vaccine, although clearly 
less than in 2006 (406). However, the recent increasing prevalence of PI-1 and PI-2 
among pneumococcal isolates could be due to an intrinsic selective advantage of the 
pili, or to their association with certain genotypes carrying some other advantageous 
feature, such as antimicrobial resistance (292).  
 
6.2.2 Pneumococcal pneumonia outbreak investigation 
Streptococcus pneumoniae is a common cause of community-acquired bacterial 
pneumonia, and it can cause outbreaks particularly in crowded settings such as in 
nursing homes (121). S. pneumoniae is reported to be the leading cause of 
pneumonia hospitalisation among military forces in the US (7, 70, 126, 127, 317). 
 
According to previous reports from Finland, the pneumococcal carriage among 
healthy military recruits has been reported to be low, ranging from 1% to 7% (178, 
180, 400). However, the pneumococcal carriage rate among healthy men has been 
reported to be up to 10 times higher during military service than at the time of 
starting service (180). In this study, the pneumococcal carriage among recruits 
during the outbreak was remarkably high (42%). In a recent study from Israel, the 
pneumococcal carriage rate among healthy recruits during the pneumococcal 
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outbreak was also reported to be very high (44%). In that study setting, the carriage 
rate dropped to <1% after the vaccination and antimicrobial intervention (15).  
 
There are several risk factors for military recruits to acquire respiratory infections, 
including pneumococcal diseases: physical and psychological stress, which may lead 
to immune depression, lack of sleep, crowded living conditions, and the mixing of 
people from diverse geographical locations (58, 59). This study demonstrated that 
the military recruits had to tolerate hard physical stress with temporarily poor 
nutrition along with dehydration in the forest encampment, which may have lowered 
their immune defence system and increased the risk of respiratory infections (120). 
The crowded living conditions may also have facilitated the transmission of 
pneumococci among the recruits and increased the nasal carriage rate (159). 
Although the rather high CRP values along with the white blood cell counts at the 
admission of recruits with hospitalised pneumonia clearly indicated the bacterial 
aetiology of the disease, the preceding viral respiratory infection may have increased 
the susceptibility to pneumococcal infection (187, 228, 378). However, no clear 
microbiological evidence of viral co-infection in the hospitalised recruits was 
detected, although the recruits complained of preceding respiratory symptoms. 
Unfortunately, the possible viral aetiology could not be confirmed because of the 
lack of convalescent sera results and since no NPA samples were taken at the time 
of preceding respiratory symptoms. Some of the recruits had respiratory symptoms 
before the encampment, although most of the recruits had their onset of respiratory 
symptom during or after the encampment. Recruits with respiratory symptoms may 
have transmitted pneumococci and/or possible viruses to other recruits during the 
encampment under strenuous conditions. 
 
In general, cigarette smoking (active and passive) is one of the well-known risk 
factors predisposing subjects to nasopharyngeal colonisation by respiratory 
pathogens and for certain respiratory tract infections (128, 347). It has also been 
proposed that cigarette smoking is the strongest independent risk factor for invasive 
pneumococcal disease among immunocompetent, nonelderly adults (259). In 
addition, it has been demonstrated that the carriage rates of S. pneumoniae are 
significantly higher among cigarette smoking recruits than non-smoking recruits 
(179). However, in this study cigarette smoking was not a significant risk factor for 
overall pneumococcal carriage, nor for confirmed or non-bacteraemic pneumonia. 
This could be due to the limited sample size. Although recent exposure to the 
antibiotics seems to be a risk factor for pneumococcal colonisation and invasive 
disease due to antibiotic-induced changes in the nasopharyngeal flora (114, 378), the 
use of antibiotics during the previous month was not associated with pneumococcal 
carriage in this study. 
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Community-acquired pneumococcal pneumonia outbreaks can be halted using 
antibiotic prophylaxis, pneumococcal vaccination, a combination of these two 
measures or without any intervention (15, 70, 75, 234, 317). No intervention for 
recruits was used to control this outbreak, because no additional pneumonia cases 
were detected.     
 
A key question of the study is why pneumococci with the same serotype and 
genotype caused life-threatening invasive disease in only a minority of the 
previously healthy military recruits, while others remained asymptomatic carriers for 
the same strain. This might be related to human genetic susceptibility. Genetic 
variation in immune response genes is associated with susceptibility to and the 
severity of infectious diseases (38, 62). Increasing numbers of studies have focused 
on finding genes related to the susceptibility to pneumococcal diseases. The genes 
encoding molecules involved in the immune response, such as Toll-like receptors, 
mannose-binding lectin and cytokines, are of special interest (38). Very rare 
mutations and common polymorphisms have previously been described in 
association with invasive pneumococcal disease (38, 278).  
6.3 Bacterial typing 
6.3.1 Molecular typing in national epidemiology and laboratory-based 
surveillance of MRSA in Finland 
Along with the other Nordic countries, Finland has been a low-incidence MRSA 
country for long time. However, within last ten years, both the incidence and the 
diversity of circulating MRSA strains have increased (184, 359). At the same time, 
MRSA typing has become more challenging. An accurate and straightforward 
typing method with high discriminatory power is needed to enable comprehensive 
nationwide laboratory-based MRSA surveillance, to detect local outbreaks and to 
perform international comparisons. In addition, the typing method should be rapid, 
relatively inexpensive and easy to perform. In Finland, the nomenclature of EMRSA 
strains has been influenced by the typing methods used at a given time. In the 1990s, 
the typing of MRSA was based on phage typing, antibiograms, ribotyping and PFGE. 
However, by the turn of the century, PFGE was used as the primary typing method 
for EMRSA identification. From the early 1990s to 2005, EMRSAs were named 
according to the geographical location where they were first identified. However, 
the naming was changed in spring 2005 to FIN names with a numeric code based on 
PFGE results. This change was made to avoid stigmatising geographical locations. 
In this study, spa typing was validated as the first-line MRSA typing tool from the 
beginning of 2009. Since then, the nomenclature has been based on spa typing 
results. spa typing has fulfilled the requirements for nationwide MRSA surveillance. 
In addition, it is useful in both outbreak investigations and international comparisons. 
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However, additional typing methods such as PFGE, MLST and SCCmec typing are 
still needed for certain circumstances. Other previous studies have come to a same 
conclusion (231, 277, 388).   
6.3.2 PFGE versus spa typing 
Since the mid-1990s, PFGE has been the gold-standard method for distinguishing 
different MRSA strains in order to monitor their spread (247, 343). However, PFGE 
is a technically demanding and a time-consuming method. In addition, its 
interpretation leaves room for subjectivity, and the comparison of results between 
laboratories remains difficult, despite the standardised protocols and interpretation 
criteria (247, 353). Moreover, PFGE was originally developed for outbreak 
investigations and its high discriminatory power can mislead the interpretation in 
long-term epidemiological investigations (32, 351, 353).  
 
In recent years, sequence-based spa typing has been shown to be reliable tool for 
typing MRSA isolates. Compared to PFGE, spa typing is more rapid, easier to use, 
and data interpretation is unambiguous. In addition, the data are easily exportable 
and used for international comparisons (3, 136, 329). Although spa typing has 
recently become a prime alternative to PFGE for typing S. aureus strains, in some 
instances the discriminatory power of spa typing is not as high that of PFGE, and it 
is not sufficient to discriminate outbreak strains (231, 277, 388). In addition, spa 
typing is based on only a single locus in the genome, and clustering of spa typing 
data can be complicated (322). The BURP algorithm is used to group spa types, and 
previous studies have shown that the concordance between spa groups (spa CC) and 
alternative methods is high (135, 343). However, ‘group violations’ associated with 
certain BURP groups and clonal lineages have been demonstrated (135, 342). These 
differences are possibly caused by recombination events in the spa locus, and the 
results from the BURP grouping method must therefore be interpreted with caution 
(135, 295). 
 
spa typing was more rapid to perform, but more expensive compared to PFGE. 
Other studies have shown similar results (55, 122, 322, 341). However, the time 
required for PFGE and spa typing depends, though not directly, on the number of 
isolates that are processed at a time. In this study, due to practical reasons, the 
number of isolates processed at a time was 24 in spa typing, but only 12 in PFGE. In 
addition, the measurements demonstrated that the time required for the interpretation 
of PFGE patterns varied considerably.  
 
The typeability of PFGE among MRSA isolates was 100%, and only three isolates 
were non-typeable by spa typing (99.5%). The typeability of PFGE among human 
MRSA isolates has also been virtually 100% in other studies (80, 105, 231). The 
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typeability of spa typing has additionally been shown to be mainly 100%, although 
Faria et al. demonstrated a lower typeability (98.3%) (80, 105, 231). Non-typeability 
by spa typing might be a consequence of mutations in the flanking conserved 
regions of the X region, which is used for primer design, leading to amplification 
problems (197). Although the typeability of PFGE has been 100% among human 
MRSA strains, certain livestock-associated MRSA strains (ST398) are not typeable 
by this method (20). However, other restriction enzymes than SmaI can be used to 
differentiate livestock-associated MRSA strains by PFGE (290). Strain identification 
is crucial before bacterial typing to ensure accurate typing results. Bacterial 
identification must especially be verified in cases of non-typeable typing results. 
 
PFGE and spa typing both had good discriminatory power (DI values). PFGE had a 
higher discriminatory power than spa typing in publication I. However, this result 
was biased, because the data were already previously recognised and selected for 
this study. When the blood isolates of MRSA strains were typed, spa typing had a 
higher DI than PFGE, although the discriminatory power of spa typing, evaluated in 
other studies, was found to be similar or somewhat lower compared to PFGE (135, 
197, 277, 343). However, PFGE results were not interpreted at the subtype level, 
which affected the DI of this method. Although the two methods measure different 
markers of genetic variation of S. aureus, they both have a good ability to 
discriminate isolates. spa typing targets the polymorphic repeat region of the spa 
gene, whereas PFGE targets the whole genome of S. aureus. Epidemiological 
interpretations of related PFGE patterns depend on the temporal scale of the study 
(32). In addition, the mutation rate of the given bacterial clone affects the pattern 
stability of PFGE (32, 351). Although the spa region has been shown to be rather 
stable, the relationship between variability in the spa region and the overall 
evolution of the S. aureus genome is not yet fully understood, and it may vary 
between S. aureus clones (111, 197, 329).   
 
Besides a high discriminatory power, spa typing has been shown to be in good 
concordance with PFGE at the type level or between clusters (105, 135, 197, 343). 
This was also the case this study, in which the results were strongly correlated 
between PFGE (at the cluster level) and spa typing, and between PFGE (at the 
cluster level) and spa CC analysed by Ridom software. However, the concordance 
between these methods was lower when analysed by AR, especially among the 44 
EMRSA strains studied. Faria et al. reported that the concordance measure, Rand’s 
coefficient, used in Ridom StaphType software leads to overestimation of the 
agreement between two typing methods and should be avoided (105, 297). The AR 
coefficient corrects Rand’s coefficient and is more suitable for concordance analysis. 
This work, as well as previous studies, has shown low AR values for typing methods 
of staphylococci (105, 236). A clear difference was noted in concordances calculated 
with AR between publication I and II. This could be explained by the difference 
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between the two data sets used. In publication 44, representatives of all Finnish 
EMRSA strain types were used. These strains were already known to be different 
based on old strict PFGE interpretation criteria, whereas publication II covered 
heterogeneous MRSA blood isolates (n = 124) between 1997–2006.  
 
The short- and long-term correspondence between PFGE and spa typing was high 
among FIN-4 and FIN-16 isolates. However, the long-term correspondence between 
PFGE and spa typing varied among the MRSA blood isolates. Among the sporadic 
isolates, the short-term correspondence between the two methods was rather low. 
Although many FIN-types showed variation in spa types among MRSA blood 
isolates, the correspondence between PFGE and spa CC was high. In addition, FIN-
16 and FIN-21, which were the most prevalent spa types among MRSA blood 
isolates, showed high correspondence between PFGE and spa typing.   
 
PFGE types and clusters could convincingly predict spa CC calculated by the 
Wallace coefficient. In addition, spa types were highly predictive of the PFGE type 
in publication II. However, in publication I the spa types had only a 57% probability 
of predicting PFGE clusters. Similarly, Faria et al. reported that the predictive power 
between PFGE (at type and subtype level) and spa type was low among MRSA 
isolates (105). They also found that the PFGE type and PFGE subtype highly 
predicted the spa CC. 
 
Overall, in publications I and II the interpretation of the PFGE band profiles was 
challenging due to the long time frame of the studies. For publication II, PFGE 
typing was performed as part of earlier national MRSA surveillance and PFGE 
profiles were used again for methodology comparisons. The genetic changes in the 
bacterial genome within the bacterial population during long time frame and the 
high discriminatory power of PFGE may have misled the interpretation.  
 
The use of a different PFGE nomenclature system between publication I and II may 
cause confusion. For clarification, in publication I, PFGE profiles with a 3–6 band 
difference were indicated by letters after the FIN number, whereas in publication II 
subtypes were not assigned. Therefore, the ‘PFGE type’ in publication II 
corresponds with the ‘PFGE cluster’ in publication I. However, the interpretation 
criteria used for analysing the PFGE profiles were the same in both studies. 
 
Recently, MLVA was validated for S. aureus. MLVA has been shown to be an 
efficient, relatively inexpensive and highly discriminatory genotyping method for S. 
aureus strains (322). In addition, it is reported that there is congruence between 
MLVA, spa typing and PFGE (322). Moreover, MLVA would be better method for 
livestock-associated MRSA, since ST389 strains, also detected in Finland, are non-
typeable by PFGE (Sma I digestion) (20, 73, 312, 377). A recent study revealed that 
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MLVA could be used to discriminate LA-MRSA ST398, although PFGE was more 
discriminatory than MLVA. MLVA would also be a useful tool for MRSA typing in 
Finland.  
6.3.3 Characteristics of MLST and SCCmec typing methods 
MLST showed a high typeability and discriminatory power (94%), whereas 
SCCmec typing clearly had a lower typeability and discriminatory power (64%) 
compared to all the other typing methods used. The discriminatory power of MLST 
STs among S. aureus isolates has also been observed to be high (over 90%) in 
several other studies (61, 105, 343). The high discriminatory power of MLST is 
somewhat surprising, because MLST is generally considered to have only moderate 
discriminatory power due to the low mutation rate of the seven housekeeping genes 
(332, 346). Because of this, MLST is considered to be especially useful for long-
term epidemiological studies and in investigating the population structure and 
evolution of pathogens (96, 221). One explanation for the high discriminatory power 
of MLST in the reference studies for methicillin-sensitive and -resistant S. aureus is 
the diversity of strain collections used. The strains selected for our study and the 
three other studies were highly diverse (61, 105, 343).  
 
In general, SCCmec typing is a low discriminatory technique due to the restricted 
number of variants generated by the method. The low discriminatory power of 
SCCmec typing detected in our study was a consequence of only five different 
SCCmec types being used, because the SCCmec subtypes were not included in the 
DI calculations. Faria et al. detected a higher discriminatory power for SCCmec 
typing among MRSA isolates, but they also included the subtypes in the DI 
calculations (105). The concordance between SCCmec typing and other methods 
was low. SCCmec typing is based on analysing a mobile genetic element, in contrast 
to PFGE, MLST and spa typing methods, which analyse more stable parts of the 
genome. In addition, SCCmec typing is used in epidemiological studies to analyse 
MRSA strain transmission and evolution (346). Variation in SCCmec types within 
the same PFGE cluster, MLST CC and spa CC was observed in publication I and 
among FIN-16 PFGE types in publication II. This could be a consequence of 
different ancestors or the susceptibility of staphylococcal isolates to receiving, 
recombining and/or replacing different SCCmec elements (403). 
 
Discussion 
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7 CONCLUSIONS  
In this thesis, methicillin-resistant Staphylococcus aureus and Streptococcus 
pneumoniae were investigated in detail by using several molecular typing methods 
for various epidemiological purposes: to study the characteristics and clonality of 
EMRSA, to evaluate and compare typing methods for national laboratory-based 
surveillance of MRSA, to study the outbreak and carriage of S. pneumoniae in a 
crowded community setting, and to elucidate the association of pili with the disease 
potential of S. pneumoniae in children with AOM infection. 
 
Among Finnish EMRSA strains during 1991–2004, CC8 was the most prevalent 
MLST CC, and most of the strains belonged to spa CC 051/008. SCCmec type IV 
was predominant and over half of the strains were multiresistant to antimicrobials. 
Only two of the EMRSA strains were positive for PVL encoding genes. Among two 
EMRSA strains, PVL-positive and -negative isolates were detected. Several 
international CA-MRSA and HA-MRSA clones were recognised in Finland. MRSA 
FIN-4 isolates as well as FIN-16 isolates were genetically closely related analysed 
by spa typing. In addition, both FIN-types belonged to only one MLST CC. Overall, 
MRSA blood isolates from 1997 to 2006 were genetically diverse. However, spa 
type t067 was the predominant spa type.  
 
The discriminatory power of spa typing, PFGE and MLST was high. The overall 
concordance values of the typing methods differed when assessed by two different 
calculation methods. The adjusted Rand coefficient showed clearly lower 
correlations for all comparisons. However, both methods agreed that the 
concordance was the highest between PFGE clusters and MLST. spa typing had a 
high probability to predict PFGE clusters, MLST ST and CC, and SCCmec types, 
depending on the study material. spa typing recognised internationally successful 
strains to also be common in Finland, and was found to be more expensive but 
approximately four times faster to perform than PFGE.  
 
An inexpensive, rapid, discriminatory and accurate typing method is required for 
national surveillance and outbreak identification, and to perform international 
comparisons. According to these results, spa typing was found to qualify as the 
primary typing method for laboratory-based MRSA surveillance in countries with a 
long history of PFGE-based strain nomenclature, and was implemented in Finland as 
a first-line typing tool from the beginning of 2009. Simultaneously, the 
nomenclature of MRSA was changed to be based on spa typing results. However, 
additional typing methods are still needed in certain situations to provide adequate 
discrimination or to characterise isolates with a newly recognised spa type in 
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Finland. In 2009, additional typing by PFGE was needed for approximately one fifth 
of the isolates in Finland.   
 
Streptococcus pneumoniae serotype 7F and genotype ST2331 was associated with 
an outbreak of pneumonia and nasopharyngeal carriage among military recruits. 
Five of the recruits were hospitalised with pneumonia and two of them had positive 
blood cultures for S. pneumoniae. An exceptionally high pneumococcal carriage rate 
was detected among the recruits. The outbreak strain covered 55% of all the 
pneumococcal findings. Although the viral aetiology of the recruits remained 
unclear, a possible viral respiratory infection along with the hard physical stress and 
crowded living conditions may have exposed the recruits to this outbreak. However, 
cigarette smoking was not found to be a significant risk factor for overall 
pneumococcal carriage, nor for confirmed or non-bacteraemic pneumonia. Moreover, 
previous antimicrobial use was not seen to be associated with pneumococcal 
carriage.  
All the pneumococcal isolates cultured from MEF or NPA of the children with 
AOM were susceptible to penicillin. The pneumococcal serotypes detected among 
these isolates were the common ones known to cause AOM infection among 
children. High heterogeneity was observed among these strains analysed by MLST. 
The pneumococcal AOM isolates detected in the time prior to pneumococcal 
conjugate vaccine and the increase in antimicrobial resistance were found to carry 
PI-1 genes at a rather low prevalence, and PI-2 genes were not found at all. PI-1 was 
found to associate with the serotype rather than the genotype. This low prevalence of 
PI-1 compared to other studies could be due to low antimicrobial resistance at the 
time when the isolates were collected. Based on this thesis, the association of pili 
with the disease potential of S. pneumoniae in AOM infections remains unsolved. 
Comparing Staphylococcus aureus and Streptococcus pneumoniae in general, 
several similarities and differences can be observed between these bacteria. Both are 
Gram-positive cocci-shaped bacteria and can cause mild to severe infections in 
humans. In addition, both can colonise the same ecological niche, the nasopharynx. 
However, the most common diseases caused by these bacteria are different. S. 
aureus commonly infects the skin and subcutaneous tissue, whereas S. pneumoniae 
is a common cause of mucosal infections such as sinusitis and AOM. From the 
various invasive infections they can cause, pneumonia and bacteraemia are common 
to both. In 2010, S. aureus was the second and S. pneumoniae the fourth most 
common blood culture finding in Finland. The antimicrobial resistance of these 
bacteria has become a major public health issue. Currently, polysaccharide and 
conjugate vaccines are available to prevent infections with several S. pneumoniae 
serotypes, but there are no licensed prophylactic vaccines for human use for the 
prevention of S. aureus disease. Both S. aureus and S. pneumoniae have extensive 
Conclusions
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numbers of different virulence factors, which play an important role in the 
pathogenesis of infections. The typing of these two important pathogens using 
various typing techniques can aid in the detection of outbreaks and in conducting 
surveillance. The purpose of the analysis should be considered carefully when 
choosing typing methods for these bacteria. In addition to the first-line typing 
methods, spa typing for S. aureus and serotyping for S. pneumoniae, techniques 
such as MLST and PFGE can be used for both bacteria. Moreover, determination of 
the presence of virulence factors encoding genes such as PVL encoding genes in S. 
aureus and pilus protein encoding genes in S. pneumoniae, can be used to 
investigate their association with the pathogenesis of the disease. S. pneumoniae is a 
diverse bacterium due to its ability to naturally take up DNA (natural genetic 
transformation). Thus, serotyping of pneumococcal isolates can be challenging due 
to capsular switching. Natural genetic transformation must also be taken into 
account when using other typing methods such as MLST and PFGE, because the 
speed at which molecular changes occur is potentially faster in S. pneumoniae than 
in S. aureus.  
Conclusions
THL  –- Research 71/2012 89 
Molecular Methods for the 
Epidemiological Analysis of MRSA  
                   and S. pneumoniae  
  
  
  
     
  
  
 
 
8 FUTURE CONSIDERATIONS 
These MRSA studies add to our understanding of the molecular epidemiology of 
MRSA strains in Finland and the importance of an appropriate genotyping method 
to be able to perform high-level laboratory-based surveillance of MRSA. A thorough 
knowledge of the characteristics of MRSA strains in Finland enables international 
comparisons. Although the number of annual MRSA cases has stabilised during the 
last couple of years, an increase in MRSA cases is possible at any time. In particular, 
the increasing number of elderly people in Finland will place a greater burden on the 
health care system, including a potential for more MRSA cases. Besides active 
MRSA control measures, rapid and adequate laboratory-based MRSA surveillance is 
still needed. However, if the number of new MRSA cases notably increases, the 
typing of MRSA strains has to be limited and typing should be directed to outbreak 
investigations. The near future will provide new typing techniques for MRSA due to 
the rapid development of new typing techniques. For example, MLVA will 
presumably offer assistance for MRSA typing in Finland in the near future. In 
addition, for research use, the DNA-based microarray technique and single 
nucleotide polymorphism (SNP) genotyping could offer a powerful tool for 
detecting virulence and resistance genes in S. aureus.  
 
Most of the MRSA strains detected in Finland are related to international clones, and 
the increasing amount of immigration and travelling will bring more foreign clones 
to Finland. Thus, travel- and immigration-related MRSA infections would warrant 
more detailed research. For example, Spain is a popular destination among Finnish 
travellers and over 400 000 people travel to Spain each year. Interestingly, spa type 
t067 is the most prevalent spa type in Finland and in Spanish hospitals. The 
connection between the spa type t067 MRSA strain in Spain and Finland would be 
interesting to study further. This type of investigation could be performed by adding 
a travel information field to the national infectious disease register form or by 
undertaking a structured questionnaire for patients with spa type t067. In addition, 
further studies on the virulence genes of this clone compared to other clones would 
shed more light on why this clone has such a powerful ability to spread. 
 
Animals may serve as a reservoir for MRSA and may transmit it to humans. In 
particular, CC398, has been reported to be common in animals such as pigs and 
horses, has been detected in humans, also in Finland. Thus, the transmission and 
spread of livestock MRSA, especially CC398, among animals and to humans needs 
further investigation. 
 
THL  –- Research 71/2012 90 
Molecular Methods for the 
Epidemiological Analysis of MRSA  
                   and S. pneumoniae  
  
  
  
      
  
  
 
 
Our study confirmed that outbreaks of invasive pneumococcal disease can occur in 
crowded environments such as in military encampments among previously healthy 
young men. Why pneumococci with the same sero- and genotype can cause severe 
invasive disease in some previously healthy young men while others only remain as 
carriers of the same strain is the main question raised by this study. Thus, further 
research could be targeted at human genetic susceptibility to pneumococcal disease. 
Future approaches will utilise genome-wide association studies to identify 
previously unsuspected genetic relations with pneumococcal diseases. 
Since the low prevalence of PI-1 among pneumococcal isolates from children with 
AOM could be due to low antimicrobial resistance at the time when the isolates 
were collected, it would be interesting to further examine the changes and pilus 
prevalence of AOM isolates in Finland nowadays, following the increase in 
pneumococcal antimicrobial resistance and the large-scale pneumococcal conjugate 
vaccination. Because the role of pili in the pneumococcal AOM infections remained 
unclear, the significance of the pilus proteins as a virulence factor in AOM 
infections and their association with the spread of antimicrobial resistance should be 
studied in more detail.  
 
 
Future Considerations
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